Evidence Report:

Risk of Decompression Sickness (DCS)

Johnny Conkin, PhD¹, Jason R. Norcross, MS², James H. Wessel III, MS²,
Andrew F. J. Abercromby, PhD², Jill S. Klein, MS², Joseph P. Dervay, MD³
Michael L. Gernhardt, PhD³

¹ Universities Space Research Association, Houston, TX
² Wyle Science, Technology & Engineering Group, Houston, TX
³ NASA Johnson Space Center Houston, TX

Human Research Program

Human Health Countermeasures Element

Approved for Public Release: date to be assigned by SMO

National Aeronautics and Space Administration
Lyndon B. Johnson Space Center
Houston, Texas
# Risk of Decompression Sickness (DCS)

**TABLE OF CONTENTS**

I. Risk Statement ........................................................................................................... 4  
II. Executive Summary .................................................................................................. 4  
III. Introduction................................................................................................................ 5  
   A. DCS Signs and Symptoms ....................................................................................... 5  
   B. Cause of DCS .......................................................................................................... 6  
      1. Supersaturation ..................................................................................................... 7  
      2. Bubble Nuclei (Micronuclei) .............................................................................. 7  
   C. Situations resulting in DCS .................................................................................... 8  
      1. Diving (Ascent from Depth) ................................................................................. 8  
      2. Ascent to Altitude / Depressurization to EVA Suit Pressure ............................. 9  
IV. Evidence .................................................................................................................. 10  
   A. Spaceflight Evidence  
      1. Potential Bias to Not Report DCS Symptoms ................................................... 10  
      2. Masked DCS Symptoms .................................................................................. 11  
      3. Operational and Gravitational Benefits of the Spaceflight Environment ........ 11  
      4. Current ISS DCS Mitigation Strategies ............................................................. 13  
         a. In-suit 4-hr Prebreathe .................................................................................. 13  
         b. Campout Protocol ......................................................................................... 14  
         c. Exercise Prebreathe: CEVIS and ISLE Protocols ......................................... 14  
      5. Retired Prebreathe Protocols .............................................................................. 16  
         a. Shuttle Staged Protocol ................................................................................... 16  
         b. Skylab ............................................................................................................. 18  
         c. Apollo and Gemini ....................................................................................... 18  
      6. DCS Modeling Evidence ..................................................................................... 19  
         a. Tissue Ratio ..................................................................................................... 19  
         b. Statistical and Biophysical Models ................................................................ 21  
         c. Modeling and Operations .............................................................................. 22  
   B. Ground-based Evidence ......................................................................................... 24  
      1. Master Logic Diagram ....................................................................................... 28  
      2. Inadequate Denitrogenation ............................................................................. 29
Risk of Decompression Sickness (DCS)

3. Activity during EVA ................................................................. 33
4. Exercise Effects on Micronuclei .............................................. 34
5. Duration of EVA ........................................................................ 37
6. Physiological Predisposition and Risk of DCS ............................. 38
7. Relationship between VGE and Hypobaric DCS ......................... 39

V. DCS Treatment Experience ......................................................... 44

VI. Risk in Context of Exploration Mission Operational Scenarios ........... 50

A. PB Protocols Meet Acceptable DCS Risk Level, but with Poor WEI and High Consumable Use .................................................. 50
B. Exploration Missions Need to Define WEI and EVA Goals .................. 50
C. Mitigating DCS through an Exploration Atmosphere may Introduce New Concerns ...... 51
D. No Exploration Atmosphere Means Longer Denitrogenation Protocols ................ 52
E. DCS Treatment is Undefined .................................................. 52

VII. Gaps ......................................................................................... 53

A. DCS1 – We have not defined the acceptable DCS risk with respect to the work efficiency index (WEI) for exploration scenarios ........................................................................ 53
B. DCS2 – We do not know the contribution of specific DCS risk factors to the development of DCS in the Space Flight Exploration Environment .......................................................... 53
C. DCS3 – We do not know the mission related factors that contribute to DCS risk ........ 53
D. DCS4 – We do not know to what extent physiological and environmental factors can be incorporated and validated in a model of DCS for micro and reduced gravity .................. 54
E. DCS5 – We do not know what validated procedures will adequately prevent DCS ....... 54
F. DCS6 – We do not know what new developments related to DCS will come from other investigators .............................................................................................................. 54
G. DCS7 – We have not validated procedures to adequately treat DCS in the spaceflight environment should it occur ................................................................. 54

VIII. Conclusion .............................................................................. 55

IX. References .................................................................................. 56

X. Team ......................................................................................... 74

XI. List of Acronyms .......................................................................... 75

Appendix A: Computer-based DCS Modeling: Description of Models ............ 77
I. Risk Statement

The Risk of Decompression Sickness (DCS) is identified by the NASA Human Research Program (HRP) as a recognized risk to human health and performance in space, as defined in the HRP Program Requirements Document (PRD). This Evidence Report provides a summary of the evidence that has been used to identify and characterize this risk. Given that tissue inert gas partial pressure is often greater than ambient pressure during phases of a mission, primarily during extravehicular activity (EVA), there is a possibility that decompression sickness may occur.

II. Executive Summary

When a diver returns from a hyperbaric environment or an aviator or astronaut travels to a hypobaric environment, the amount of inert gas in excess of what can be held in solution at the new lower pressure has the potential to come out of solution to form gas spaces that can displace or otherwise damage tissues. Unlike other spaceflight-related human risks, decompression sickness (DCS) is a known problem that has been mitigated since the first EVA. Various DCS mitigation strategies have effectively been used, including a lower pressure high oxygen environment (Gemini, Apollo, Skylab) requiring a single 4-hr pre-launch oxygen prebreathe (PB); a resting 4-hr in-suit PB; an intermediate pressure, mildly hypoxic environment requiring a single 40- to 75-min in-suit PB; and several exercise-enhanced protocols combining both mask and in-suit PB protocols. To date, DCS has been effectively mitigated through rigorous adherence to PB protocols validated specifically for the EVA environment and primarily for the microgravity (µG) environment. While effective, these protocols can be complex and require significant pre-flight training, inflight crew time, and consumable usage.

Historically, prebreathe protocols have been developed with the goal of preventing DCS and have been designed to meet operational needs. This operationally driven research has left gaps in knowledge about several DCS risk factors, including bubble formation in space, nitrogen elimination in space, breaks in PB periods, micronuclei generation, and tissue saturation, across different pressure and gas environments.

The acceptable risk for DCS has been defined in the NASA Human Spaceflight Standards; therefore, the next step will be to develop and validate procedures, protocols, and countermeasures to meet this standard effectively and efficiently for the range of nominal and off-nominal atmospheres and decompression profiles that crewmembers may experience during future exploration missions. Utilization of the Exploration Atmosphere (8.2 psia / 34% O₂), suit ports, and variable pressure suits, as well as the inability to rapidly deorbit for medical treatment, means that existing DCS risk mitigation protocols and data sets are not applicable to future exploration missions.

To improve efficiency from a sea level atmosphere, data are needed on the potential differences in bubble formation and N₂ elimination while in µG. To improve safety and efficiency from any atmosphere, data are needed to describe the consequences of a break in PB. Finally, the opportunity exists to mitigate DCS primarily through engineering controls by the use of the 8.2 psia / 34% O₂ Exploration Atmosphere, suit ports, and variable-pressure EVA suit. While promising, this strategy still requires validation to ensure it mitigates the DCS risk to acceptable
levels and to determine if there are any significant negative physiological effects associated with the Exploration Atmosphere’s mild hypoxia equivalent to an altitude of approximately 4000 ft.

III. Introduction

The overarching medical and operational philosophy is that it is better to prevent rather than to treat DCS. The advent of technology that permitted a rapid change in ambient pressure ushered in the study of new medical conditions, such as DCS and hypoxia. Robert Hooke, an assistant researcher to Robert Boyle, created the first functional vacuum pump in 1671 (Harsch 2006). Much experimental work was done on exposure to a “rarified atmosphere.” As the air compressor advanced, with steam engine power and later with electricity, it replaced the application of a bellows at the blacksmith’s hearth and soon found new uses including providing forced air to divers beneath the sea, allowing diving beyond ones’ breath-holding abilities as well as permitting experiments under hyperbaric conditions. Paul Bert’s seminal treaties on barometric pressure in 1878 codified much of the empirical experience of that day (Bert 1878). Diving technology rapidly advanced that permitted deeper and longer exposures to hyperbaric air with the accompanying DCS on the return to 1 atmosphere absolute (ATA). Several textbooks on diving chronicle the history of diving and the methods used to prevent DCS upon return to 1 ATA, as well as treatment strategies to aid those afflicted with “the bends.” A compilation of experience with hypobaric, or altitude, DCS was published by Fulton in 1951, succinctly titled, Decompression Sickness. No other book has since been published that surpasses the depth and breadth of information that lies between the covers of Fulton’s book. Much of what we know about hypobaric DCS and denitrogenation as a mitigation strategy was learned during and shortly after World War II (WWII) and was summarized in Fulton’s book. Numerous chapters and reports have since been published that include new observations (evidence) for hypobaric DCS, summarized in the following pages.

Before the very first EVA, NASA understood that DCS was a risk to be mitigated. Given the highly constrained spaceflight environment, these mitigation strategies needed to be efficient both in time and resource use. A clear understanding of the mechanisms that cause DCS is needed to efficiently mitigate this potentially catastrophic risk to the mission and the astronaut. Should DCS occur in the spaceflight environment, it would occur during an EVA, when the crewmember is already isolated from the habitat in a physically constraining spacesuit. Historically, treatment for DCS could only begin once the EVA crewmember had terminated EVA activities and returned to the habitat to be repressurized.

A. DCS Signs and Symptoms

DCS signs and symptoms are historically classified as Type I, Type II, and skin bends. At JSC, Type I symptoms are described as “pain only” DCS symptoms localized in muscle(s) or joint(s) and can include localized paresthesia and simple skin bends. Type I symptoms can result in an EVA termination/abort and jeopardize mission success. If not treated, Type I symptoms can eventually become incapacitating and jeopardize EVA crew-member recovery. Type I incapacitating symptoms are generally preceded by less severe Type I symptoms.
Risk of Decompression Sickness (DCS)

Type II symptoms are systemic, generally neurological, involving the central nervous system, or cardiopulmonary, resulting in pulmonary "chokes", circulatory collapse, shock, and even death; symptoms may also include multiple-site paresthesias. Type II symptoms require immediate EVA termination and jeopardize both mission success and crew health. Type II symptoms may or may not be preceded by Type I symptoms and may be life threatening, especially in the EVA environment if not abated by an increase in pressure and adjunctive treatment.

Cutis Marmorata is a type of skin bends more serious than Type I skin bends where the skin has a marbled or mottled appearance. It likely indicates that significant bubble formation is occurring throughout the body. At JSC, this type of skin bends is categorized separately from Type I and Type II DCS.

DCS is also associated with gas embolism (the presence of gas bubbles in the vascular system), both venous gas emboli (VGE) and arterial gas emboli (AGE). Although VGE can typically be filtered adequately by the lungs, circulating VGE is not a desired condition, especially with the presence of a patent foramen ovale (PFO), which is a hole in the wall separating the right and left atria of the heart. A PFO is a remnant of life in the womb where oxygenated blood from the placental circulation is shunted away from the pulmonary circulation of the fetus. This connection closes in most newborns, but approximately 25% of the adult population has some small patency (hole) that allows oxygenated and deoxygenated blood to mix. If denitrogenation is not effective, either due to inadequate vehicle design (either in gas constituency or atmospheric pressure, or a combination of both) or inadequate operational PB protocols, the resulting presence of VGE during an EVA could cross through a patent PFO under particular conditions and become arterialized. Many factors in the aerospace environment compromise healthy lung function. These factors, when combined with a high number of VGE entering the pulmonary circulation, can put astronauts at high risk for arterIALIZING VGE that are normally filtered by a healthy lung. AGE put the astronaut at risk for vascular blockages and resulting ischemic damage to the brain or other organs.

Although the displacement of tissue by trapped gas spaces or the disruption of metabolic function due to embolic obstruction of blood flow can cause a wide range of signs and symptoms, the historical approach to DCS mitigation at NASA has been very conservative with the goal of preventing DCS. One consistent observation concerning test subjects at the Johnson Space Center (JSC) is that pain-only DCS after significant denitrogenation is predominately found in the lower body, particularly associated in or around the patella (Degner et al. 1965, Ryles & Pilmanis 1996).

B. Cause of DCS

There are two conditions necessary for the development of DCS. The first condition is inert gas supersaturation, defined as a tissue inert gas partial pressure greater than ambient pressure. The second condition is the presence of a bubble nuclei (micronuclei) from which the supersaturated tissue inert gas can evolve into a gas bubble.
1. Supersaturation

A fundamental axiom about DCS is that a transient gas supersaturation, also called over-pressure or pressure difference ($\Delta P$), exists in a tissue region; the sum of all gas partial pressures in that region is greater than the ambient pressure opposing the release of the gas. Expressed as an equation, supersaturation exists when $\Delta P$ is positive:

$$\Delta P = \sum_{i=1}^{n} (P_i - P_2)$$  \hspace{1cm} (Eq. 1)

where $P_i$ is the dissolved gas tension of the $i^{th}$ gas of $n$ species in the tissue and $P_2$ is the ambient pressure after depressurization. The potential for bubble nucleation and rate of bubble growth are a function of the supersaturation.

Gas supersaturation in the tissue is not in itself harmful, but it is a thermodynamically unstable condition between the tissue and the surrounding environment. The difference between tissue gas partial pressure and ambient pressure is easily resolved with a phase transition, and some of the excess mass (moles) of gas in the form of bubbles may be accommodated by the tissue and cause no symptoms. However, whenever a gas space is formed due to partial or complete desaturation of a supersaturated tissue, there is some probability of DCS [$P(DCS)$] (Weathersby et al. 1984). A necessary condition for DCS is the formation of a gas phase in the tissue. The assumption that pain results from the deformation of tissue past a critical point due to evolved gas may not account for symptoms other than pain-only DCS, but evolved gas is certainly the primary insult for all subsequent signs and symptoms. It is not the presence or even the volume of evolved gas in the tissue that is important in pain-only DCS, but rather the pressure difference between the gas space and the tissue. The pressure difference was termed “deformation pressure” by Nims (1951).

2. Bubble Nuclei (Micronuclei)

The previous discussion focused on reducing the amount of tissue $N_2$ to limit bubble growth, which is the classic Haldanean approach. However, an emerging area of DCS prevention is to also hinder the transformation of tissue micronuclei into growing bubbles (Tikuisis & Gerth 2003, Blatteau et al. 2006). The presence of gaseous micronuclei in the tissues permits DCS under modest depressurizations (Weathersby et al. 1982). Information about and evidence for tissue micronuclei come mostly from indirect observations. The application of a high-pressure spike, either hydraulic or pneumatic, filtration, or ultracentrifugation of a sample are all accepted means by which to reduce the number and size of micronuclei (change the distribution), evident from fewer bubbles or cases of DCS after a subsequent depressurization (Evans & Walder 1969, Ikles 1970, Vann et al. 1980). One inference from these studies is that normal activity establishes a size distribution of micronuclei within tissues, which can be modified by changing activity levels. The idea of “using up” micronuclei faster than they are generated as a means to understand increased resistance to DCS due to repeated exposures has also been discussed (Hills 1977). A comprehensive review and discussion of micronuclei is not provided here, but information is available in Hills 1977, Hemmingsen 1989, Powell et al. 1993, 1995, Butler et al.
Risk of Decompression Sickness (DCS)


C. Situations Resulting in DCS

Humans are typically subjected to Earth-normal atmospheric pressure at sea level (1 ATA, 14.7 psia, 101.3 kPa, 760 mmHg) and Earth-normal gravity (1 G). This Earth-normal atmosphere is just one pressure in a range of higher and lower pressures where humans can comfortably exist. It is the rapid transition from higher to lower pressure that is the primary concern for DCS.

1. Diving (Ascent from Depth)

Long before humans could ascend to high altitudes, including space, they could dive to modest depths using compressed air or be exposed to modest depths through the application of caissons. Diving on compressed air or exposure to compressed air in a caisson allowed nitrogen (N\textsubscript{2}) to accumulate in tissues, based on the solubility of N\textsubscript{2} in the tissues and the delivery of N\textsubscript{2} by the circulatory system. Ascent limits for these “non-saturation” exposures were empirically derived based on avoiding supersaturation of mathematically derived tissue half-time compartments.

The type (depth and duration) of the dive defined the controlling half-time compartments to limit the supersaturation specific to the compartment. Eventually, divers would remain long enough at an increased pressure to the point where no additional N\textsubscript{2} would be absorbed by the tissues at the new saturation depth; these are called saturation exposures. Ascents from saturation exposures are slower than those for non-saturation exposures because the total dissolved N\textsubscript{2} is greater and the high N\textsubscript{2} partial pressure has come into equilibrium in tissues with long half-times, which require longer times to denitrogenate during ascent back to 1 ATA.

DCS is a known risk in the diving community and is mitigated through diver training and through the widespread use of decompression tables or dive computers, which determine dive time limits, ascent rates, and decompression stops. DCS due to diving is not the focus of this report. For a more detailed discussion on DCS due to diving and dive physiology, the reader is referred to references such as Bennett and Elliott’s Physiology and Medicine of Diving (Brubakk and Neuman, 2003).

The focus of this evidence report is on preventing DCS during EVAs, but an EVA is just the culmination of many hours of training under both hyperbaric and hypobaric conditions. For ISS assembly EVAs, it was normal for a crewmember to train for EVA procedures in the JSC Neutral Buoyancy Laboratory (NBL) at a ratio normally exceeding 10 NBL hours per 1 EVA hour (Williams and Johnson, 2003).

Policies and procedures are followed that minimize the P(DCS) after hyperbaric suited exposures in the NBL and the Russian Hydrolab during suited exposures in hypobaric chambers and after diving activities associated with the NASA Extreme Environment Mission Operations (NEEMO) underwater habitat. For example, the objectives of an EVA are choreographed on flight-like hardware submerged in 40 feet of fresh water (FFW) at the NBL. Training emulates actual EVA scenarios and can last for 6 hours. To avoid DCS after long exposures to a maximum physiological depth of 50 FFW (pool depth plus suit pressure), astronauts breathe nitrox, a mixture of 46% O\textsubscript{2} and 54% N\textsubscript{2}. At this extreme, the equivalent air depth is 23 FFW. Breathing...
Risk of Decompression Sickness (DCS)

Nitrox eliminates the need for staged depressurization at the end of a long training session, and some details about the NBL’s diving practices are available from Fitzpatrick & Conkin (2003).

Astronauts also train and maintain proficiency in operating the spacesuit under hypobaric conditions in various altitude chambers at JSC. In some cases, astronauts are required to fly in the T-38 aircraft or on commercial airlines shortly after a hyperbaric or hypobaric exposure. Specific directives, based on best available research (Horrigan et al. 1989, Vann et al. 1993, Pollock & Fitzpatrick 2004), dictate the proper surface intervals and PB procedures that minimize the P(DCS) in a subsequent hypobaric exposure.

Procedures and equipment are available to treat DCS on orbit and after training activities, and a disposition policy (NASA JSC JPD 1800.2b) returns astronauts to flight status after a successful treatment regime. Adherence to these policies and procedures, which undergo periodic review and updating, minimizes the probability that DCS will become a medical concern to the astronaut or will hinder the completion of training or safe execution of an EVA.

2. Ascent to Altitude / Depressurization to EVA Suit Pressure

A diver experiencing DCS will do so upon return to the surface after completing their dive; treatment in such circumstances typically begins almost immediately and requires little action on the part of the patient. In contrast, an aviator that has lost cabin pressure or an astronaut during an EVA in a spacesuit could be afflicted with DCS during the performance of their tasks. These tasks are left unfinished, and the aviator/astronaut must typically return themselves or be returned to a safe environment and configuration by a co-pilot or EVA partner before treatment for evolved gas can be initiated. Thus, in addition to the health risk associated with any occurrence of DCS, an occurrence of DCS during spaceflight carries the additional risk associated with delayed initiation of treatment as well as the secondary concern of the potential for loss of productivity.

The most effective way to reduce P(DCS) is to reduce the ΔP between environments (described in Eq. 1) by reducing $P_1$ (cabin inert gas [primarily $N_2$] partial pressure), increasing $P_2$ (suit pressure), or utilizing some combination of both to achieve acceptable risk and operational efficiency. A spacesuit is a flexible spacecraft, and details about U.S. spacesuits are available from Thomas and McMann (2011). The current NASA spacesuit, called the Extravehicular Mobility Unit (EMU), operates at 4.3 psia, or 222 mmHg, above the vacuum of space (Powell et al. 1994a, Locke 2008). Current EMU suit technology, especially the design of the gloves, does not permit a high-pressure suit without causing increased fatigue, reduced mobility, and decreased manual dexterity, whereas the Russian Space Program accepts some of these human performance decrements and operates the Orlan suit at a pressure of 5.8 psia. Historically, reducing the risk of DCS by increasing the suit pressure has caused significant operational limitations, but developments are underway to develop a flight-ready variable-pressure suit capable of operating effectively between 3.7 and 8.3 psia.
IV. Evidence

A. Spaceflight Evidence

Astronauts and cosmonauts working in spacesuits pressurized to between 3.7 and 5.8 psia have not reported DCS during EVAs. In contrast, U.S. and Russian research subjects who evaluate operational PB protocols in altitude chambers report DCS at a rate of approximately 20% (Conkin et al. 2003). How are these disparate observations reconciled? Technicians have reported pain-only DCS at JSC during suit development (two cases are documented in an internal NASA Investigation Report from 1988), and at least 1 astronaut recollected pain (after the spaceflight) in a knee on 2 occasions after depressurization to 5.0 psia in the spacecraft (Hawkins & Zieglschmid 1975). Foster & Butler (2009) discussed several factors related to working in a hypobaric and μG environment that may reduce the P(DCS) in EVA astronauts, which are summarized in this section.

1. Potential Bias to Not Report DCS Symptoms

A research setting designed specifically to monitor for DCS is different from an operational setting where a highly trained and motivated crewmember is performing an EVA, which is considered one of the pinnacles of an astronaut’s career. Even if DCS symptoms have occurred, there may be a bias to not report mild discomfort in this type of operational setting, especially if symptoms are not limiting. NASA’s current policy is that every test subject and every crewmember who participates in hyperbaric or hypobaric operations is required to immediately report the onset of any DCS symptoms (NASA JSC JPD 1800.2b).

Under-reporting of DCS symptoms is routinely observed in pilot training, where qualification to fly is compromised if DCS is reported during hypobaric training activities. This is discussed relative to the high-altitude U-2 pilot community (Bendrick et al. 1996 and Hundemer et al. 2012), which highlights differences between operational and research reports of DCS. According to Bendrick et al. (1996), 75% of 273 active-duty and retired U-2 pilots responding to an anonymous questionnaire said that they had DCS symptoms at least once during their careers flying U-2 aircraft but rarely reported their symptoms to the flight surgeon (Meader 1967). Webb et al. 1996 reported a DCS incidence of 77% in subjects testing the 60-min U-2 PB protocol, which included mild exercise while at a simulated aircraft cabin pressure of 4.37 psia. Intense, short-duration exercise during this PB reduced the incidence to 42% in subjects and is offered to U-2 pilots who feel the need for additional DCS protection (Hankins et al. 2000).

The only anecdotal report of a DCS symptom in an astronaut during spaceflight was reported several years after the flight in a personal autobiography rather than real-time to the flight surgeon (Hawkins & Zieglschmid 1975). For various reasons, astronauts and pilots are not motivated to report every small discomfort (Jersey et al. 2010). As a result, it is possible that the first report of DCS during an EVA will be a serious case of DCS (Conkin 2001).
2. Masked DCS Symptoms

There are various reasons why mild symptoms of DCS may be masked during an EVA. Many astronauts take aspirin before an EVA, so mild aches and pains are managed in advance. The EMU is a source of aches and pains of the same intensity as pain-only DCS. As such, many mild cases of DCS that are not reported during an EVA could be attributed to pain caused by working in the EMU. Because mild symptoms quickly clear during repressurization, astronauts would have little incentive to report a symptom that is no longer present after the EVA. The incidence of DCS symptoms that would interfere with performance in an EMU was less than 5% in validation testing in altitude chambers (Waligora et al. 1984, Conkin et al. 1990). Approximately 85% of those with symptoms showed improvement in the symptom or showed no change in symptom intensity when tests were allowed to proceed past the point of the first symptom report. Because PB protocols before EVA reduce the incidence and intensity of symptoms, it is understandable that any resulting mild symptoms are unremarkable in an operational setting.

3. Operational and Gravitational Benefits of the Spaceflight Environment

It is also possible that DCS has not actually occurred during an EVA (Powell et al. 1995, Gernhardt et al. 2004). The situation of subjects wearing an O₂ mask who are otherwise comfortable in a shirtsleeve environment at 1-G is not the same as that faced by astronauts surrounded by 100% O₂ and maneuvering in µG with limited mobility and uncomfortable spacesuits. Limited motion in the Orlan, and, by extrapolation, the EMU, is hypothesized to be a significant factor in reducing the likelihood of DCS during an EVA.

Astronauts perform more conservative prebreathing in space than is tested on the ground, as ground-based PBs are performed in accordance with Aeromedical Flight Rules, and more than the minimum protection is always provided. Based on a detailed analysis of actual PB episodes performed on-orbit, the tissue ratio (TR), or R-value, computed for the first 142 staged PB protocols from the Shuttle was 1.51 ± 0.07, compared with 1.52 ± 0.26 for 245 research subjects at JSC who had a DCS rate of 18% and who were ambulatory during testing (Conkin et al. 2006). Ambulation encourages DCS and VGE from the lower body, so the absence of ambulation in µG likely reduces the incidence of DCS below 18% during EVA (Conkin et al. 2006). During the Shuttle staged protocol, the TR also decreased during subsequent EVAs, from 1.51 to 1.48 for the second EVA. This is because breathing 100% O₂ during a 6-hr EVA continues the denitrogenation process over multiple EVAs during a Shuttle mission, as well as because the crew lives at 10.2 psia / 26.5% O₂, where tissues eventually equilibrate to a pN₂ of approximately 7.5 psia. Waligora & Pepper 1995 and Waligora & Kumar 1995 summarized physiological aspects of working in space during the first 59 Shuttle person-EVAs.

In addition to added PB duration, we also need to understand if the primary risk mitigation strategy of prebreathing is more or less affected by adaptations to µG. All astronauts undergo adaptation to µG (Nicogossian & Parker 1982). Approximately 2 liters of fluid from the lower extremities is redistributed to the chest and head, with a resulting decrease in total body water. The upper body venous engorgement at the expense of a reduced lower body venous capacitance does not abate even after months in space, even following the net decrease in plasma volume.
As a result of this fluid shift, denitrogenation in $\mu$G may be more efficient than that on Earth if a supine body position is a reasonable analog for $\mu$G (Balldin 1973).

Lesser interventions than adaptation to $\mu$G are known to modify $N_2$ washout (Pendergast & Olszowaka 1989, Margaria & Sendroy 1950). Jones et al. (1945) performed early work in understanding the effects of blood perfusion on $N_2$ uptake and elimination in tissues. Behnke et al. (1935, 1937, 1941) showed how body composition and exercise during PB influenced $N_2$ removal. Studies by Balldin et al. (1971, 1972, 1973, 1978) showed how increased ambient temperature, supine body position, and immersion in water increased $N_2$ removal from adipose and muscle tissue, as well as from the entire body. Theis et al. (1979) confirmed and supplemented these data by examining whole-body $N_2$ washout associated with the supine body position. Balldin & Borgstrom (1977) and Curry & Lundgren (2003) reported that even negative-pressure breathing accelerates $N_2$ washout. The most recent efforts to understand $N_2$ removal under various experimental conditions, including $\mu$G simulation, were by Vann & Gerth (1995) and Gerth et al. (1987, 1989). Various experimental interventions resulted in a wide range of tissue $N_2$ washout from approximately 8 ml/kg for seated subjects to approximately 24 ml/kg for subjects who performed 50 watts of continuous arm and leg exercise for 2 hr while at a 6-degree head-down tilt during a 3-hr PB. Thus, it is reasonable to hypothesize that the altered physiology and anatomy in response to $\mu$G adaptation modifies, in an unknown manner, the amount of $N_2$ removed from the body during PB (Conkin et al. 1983, Powell et al. 1992, Conkin & Powell 2001).

For a portion of any operational PB and all of an EVA, the astronaut is surrounded by 100% O$_2$. It is unclear how much $N_2$ is transferred out of the body through the skin of astronauts or into the body of subjects surrounded by air in altitude chambers; however, any benefit would go to the astronaut (Groom & Farhi 1967). A warm ambient temperature enhances denitrogenation (Balldin 1973). Shuttle astronauts often reported that they were cool to cold during EVAs. It is likely that research subjects are in a more comfortable thermal environment during a PB and EVA simulation than astronauts. It is unclear how skin temperature that is cool due to the Liquid Cooling and Ventilation Garment affects the transport of $N_2$ across the skin during the in-suit portion of the PB and during the EVA. Conclusive knowledge regarding $N_2$ washout in space or unbiased information from an in-suit Doppler bubble detector would greatly aid in understanding the true risk of DCS in EVA astronauts (Barer et al. 1995a, Conkin et al. 1996a, Conkin et al. 1998, Thompson et al. 2002).

Astronauts are physically active during PB, and exercise during PB accelerates $N_2$ washout (Loftin et al. 1997, Webb et al. 1996, Pendergast et al. 2012). Subjects in early trials at JSC were inactive during PB periods. Aerobic fitness, as measured by VO$_2$ peak, is not per se associated with resistance to pain-only DCS. An analysis of VO$_2$ peaks in subjects failed to show a strong association with DCS in exposures without PB and with resting PB. However, the association was strong when exercise was included as part of the PB protocol (Conkin et al. 2007, Pollock et al. 2004a). The benefit of exceptional aerobic fitness in reducing the P(DCS) is only realized when exercise is exploited as part of the PB protocol. A person with a low VO$_2$ peak can reduce their P(DCS) to match that of a fit person by increasing the intensity of exercise in the same PB time, increasing the length of the PB, or utilizing some combination of both (Conkin et al. 2007, Conkin et al. 2004).
Cumulative O\textsubscript{2} consumption during PB is not the only consideration necessary for reducing the P(DCS). Effective N\textsubscript{2} elimination seems to depend on how the exercise is performed to a greater extent than just total O\textsubscript{2} consumption per unit time normalized to body mass. Additionally, there are constraints regarding the type and duration of exercise prescribed during the PB because a long EVA awaits the astronaut after the PB. Women research subjects did not benefit to the same degree as men with respect to %VO\textsubscript{2} peak when exercise during PB was prescribed (Conkin 2010). Astronauts as a group are more physically fit than their age-matched research subject counterparts. Current astronauts are approximately 10 years older than research subjects but have similar aerobic fitness as measured by VO\textsubscript{2} peak. Therefore, subjects who would be aged-matched to the astronaut population would be less fit. If fitness is linked to DCS susceptibility (Webb et al. 2005, Carturan et al. 1999, 2002), then astronauts as a group under any PB condition may be less susceptible to DCS than subjects of a comparable age (Conkin et al. 2003). Finally, the “effective” exercise in the EMU may be less than or different from exercise on Earth used to simulate EVA activity, and exercise is certainly an important consideration for DCS risk at altitude.

4. Current ISS DCS Mitigation Strategies

Different missions require different strategies to avoid DCS. In every case, a detailed analysis (trade process) eventually defines the appropriate PB protocol. We provide a summary of PB protocols that are currently in successful use, along with any lessons learned along the way. ISS astronauts currently have available three denitrogenation strategies to reduce the P(DCS): resting PB, staged denitrogenation, and exercise PB.

The desire to perform science with μG as the primary variable led NASA to select an Earth-normal atmosphere for the Shuttle and the ISS. The Russian space program had already committed to an Earth-normal atmosphere, even before the Mir space station was launched. A consequence of these decisions was that EVAs in the 4.3 psia EMU and the 5.8 psia Russian Orlan spacesuit could result in DCS, so efficient and effective denitrogenation protocols were needed. Compounding the challenge is that an air break (brief exposure to high partial pressure of N\textsubscript{2} (pN\textsubscript{2})) during a 100% O\textsubscript{2} PB is unavoidable if transitioning O\textsubscript{2} delivery from a shirt-sleeve mask to the EVA suit. This issue requires research to understand and procedures to compensate for air breaks during PB.

a. In-suit 4-hr Prebreathe

In the simplest resting PB protocol, the astronaut breathes 100% O\textsubscript{2} in the spacesuit for 4 hr. The 4-hr duration was determined as being necessary to achieve an acceptable P(DCS) based on the type and amount of work to be done in the suit and the duration of the hypobaric exposure (Conkin et al. 1987). The operational challenge is to match the length of PB with an acceptable low incidence of DCS (Waligora et al. 1987) to produce an efficient EVA. Waligora et al. (1984) described tests of 3.5- and 4-hr PBs at JSC, which evolved into the current operational 4-hr in-suit PB. The 4-hr in-suit PB has been used 6 times during spaceflight with no reported DCS. A 4-hr PB immediately prior to performing an EVA that could last up to 8 hr represents an inefficient use of crew time, makes the crew duty day over 14 hr on EVA days, and inefficiently uses up suit consumables.
b. Campout Protocol

A modification of the Shuttle staged protocol, called the campout protocol, is now used on the ISS, which significantly reduces the required in-suit PB duration by having the two EVA crewmembers “camp out” in the ISS airlock at 10.2 psia, 26.5% O₂ during the night prior to their EVA. For various operational reasons, the time at 10.2 psia is limited to 8 hr and 40 min, most of which is spent sleeping. The lack of food preparation and personal hygiene facilities in the airlock means that a post-sleep repressurization to 14.7 psia is required prior to suit donning. During this break, the 2 astronauts breathe 100% O₂ by mask for 70 min while gathering food and using the restroom. Upon return to 10.2 psia, 26.5% O₂, the masks are removed, and the suit-donning process is completed. The airlock is repressurized to 14.7 psia after the astronauts don their spacesuits to allow an assistant to exit at 14.7 psia and to complete the 50-min in-suit PB before the final depressurization of the airlock to the vacuum of space with the suits remaining at 4.3 psia.

After extensive review, the similarity of the campout PB to the Shuttle staged PB (described in Section 4.5.1) along with good operational experience with the Shuttle staged protocol negated an empirical validation of the campout PB. The first EVAs on the ISS using the campout protocol took place in September 2006, with approximately 145 person-EVAs completed by August 1, 2013.

This more complicated staged PB protocol was favored over a simpler in-suit PB protocol. The use of the staged protocol reduces fatigue in astronauts, who would otherwise be in the spacesuit for 10 to 12 hr, and increases the efficiency of the astronauts, as time that would otherwise be unproductive during a 4-hr in-suit PB can be spent on other tasks. The only way to reduce fatigue and maintain efficiency while using the in-suit PB protocol is to perform the majority of the PB while using a mask outside of the suit, but this eventually requires a transition from the mask to the suit. Because the suit requires a 100% O₂ purge and leak check, the transition from a mask, or even a mouth piece and nose clip, to the suit with 100% O₂ without an air break has proven unavoidable.


c. Exercise Prebreathe: CEVIS and ISLE Protocols

After the ISS Quest airlock was delivered on STS-104.7A in July 2001 and before the campout protocol was available in September 2006, an option to perform exercise-enhanced denitrogenation from the ISS became available. An accelerated denitrogenation protocol was needed to avoid scheduling constraints on EVAs performed from the ISS; additionally, because N₂ elimination and uptake is a perfusion-limited process, the use of exercise during the PB is an effective method of accelerating denitrogenation. The ambitious goal was to reduce the available 4-hr resting in-suit PB by approximately 50%.

Before the delivery of the Quest airlock, EVAs to support ISS construction were performed with hatches closed between the 2 vehicles so that the Shuttle 10.2-psia PB could be used. The first use of the exercise PB protocol was to complete the installation of the ISS airlock. The discomfort and complexity of adding an effective interval of exercise during PB must be balanced with the rewards, namely less total PB time and greater reduction in the P(DCS) from
an alternative resting PB, or the option is not acceptable to the astronaut. No single, reasonable, short-term intervention can increase cardiac output as much as exercise. Exercise during PB was evaluated during and shortly after WW II (Behnke & Willmon 1941, Webb et al. 1943, Boothby et al. 1952) and reevaluated at Brooks Air Force Base (AFB) for the special operations community (Webb et al. 1989, 1996, 1998, 2002, 2004, Hankins et al. 2000) and, most recently, by NASA. Details regarding approximately 9 exercise PB options evaluated by NASA from 1997 to 2009 are available in the papers by Gernhardt et al. (2000, 2003), Conkin et al. (2004), and Loftin et al. (1997) (also see Table 3).

Two exercise PB protocols acceptable for operations on the ISS are briefly described below: the Exercise PB protocol using the cycle ergometer with vibration isolation and stabilization (CEVIS) device and the In-suit Light Exercise (ISLE) PB protocol using the EMU as a resistive exercise device.

**Cycle Ergometer with Vibration Isolation and Stabilization (CEVIS) Protocol:**

For the CEVIS Exercise PB protocol, prior to launch, the astronaut performs a peak O\(_2\) consumption (VO\(_2\)) test using leg ergometry, and a linear regression of VO\(_2\) versus watts (work-load) is created for that individual. An exercise prescription is produced that distributes the appropriate work-load between the upper body (12%) and lower body (88%).

During on-orbit EVA preparations, the astronaut breathes O\(_2\) from a mask and performs 3 min of incremental exercise on the CEVIS at approximately 75 revolutions/min using a prescription that increases the workload from 37.5% to 50.0% and then to 62.5% of their VO\(_2\) peak while also rhythmically pulling against elastic surgical tubing to include upper body activity. The ergometry is complete after an additional 7 min at 75% of VO\(_2\) peak.

After waiting an elapsed time of 50 min while still breathing 100% O\(_2\) from the mask, the EVA astronauts and the IVA crewmember depressurize in the ISS airlock to 10.2 psia over 30 min. During the depressurization period, the liquid cooling garment and the lower portion of the spacesuit are donned. Once the airlock O\(_2\) concentration stabilizes at 26.5%, the astronauts and IVA crew attendant remove the masks and complete the donning of the upper torso of the spacesuit. Thus, for a significant portion of the PB duration, the astronaut is physically active in the suit-donning process. A leak check and then a purge with 100% O\(_2\) to remove N\(_2\) from the suit complete the suit-donning procedure.

The in-suit PB starts in conjunction with a 5-min repressurization back to 14.7 psia, under which the remaining 55 min of the in-suit PB is performed and the IVA crewmember exits the airlock. The final depressurization of the airlock to the vacuum of space and to 4.3 psia in the suit takes 30 min. The CEVIS Exercise PB has been used 50 times as of 08/01/13 with no reported DCS.

**In-Suit Light Exercise (ISLE) Protocol:**

For the ISLE PB protocol, the astronaut does not perform a short bout of intense PB exercise on the CEVIS prior to suit donning at 10.2 psia but instead performs a longer period of mild exercise in the EMU. The ISLE protocol shares many steps with the Exercise PB protocol but differs in that 40 min are spent breathing 100% O\(_2\) by mask followed by a 20-min
depressurization to 10.2 psia. Once suit donning is complete, arm and leg motions are performed for 4 min, followed by 1 min of rest in conjunction with a 5-min repressurization back to 14.7 psia. The mild exercise pattern continues for 50 min and achieves a minimum VO\textsubscript{2} of 6.8 ml·Kg\textsuperscript{-1}·min\textsuperscript{-1}. An additional 50 min of resting PB completes the protocol, followed by a 30-min depressurization of the airlock to vacuum. The ISLE PB has been used 16 times as of 08/01/13 with no reported DCS.

**Combining Exercise with Intermittent Recompression:**

The return to 14.7 psia after a short suit donning period at 10.2 psia in both the Exercise and ISLE PB protocols, as well as the 2 returns to 14.7 psia over the course of the longer campout PB, likely reduced the subsequent P(DCS) through removal of silent bubbles. These bubbles had the potential to form from a limited number of large-radius micronuclei during the initial depressurization to 10.2 psia. Once formed and then reabsorbed during the repressurization to 14.7 psia while breathing 100% O\textsubscript{2}, the tissues are temporarily left with micronuclei with a smaller range of radii from which bubbles can be formed during the final depressurization to 4.3 psia. This did not occur during the Shuttle 10.2 psia staged depressurization protocol. The entire habitable volume of the Shuttle was depressurized, so the astronauts simply continued the depressurization from 10.2 to 4.3 psia after suit donning in the airlock.

5. **Retired Prebreathe Protocols**

The remainder of this section is a brief historical summary of PB protocols that were successful, with lessons learned along the way.

a. **Shuttle Staged Protocol**

In the Shuttle staged denitrogenation strategy, the ambient pressure was decreased to an intermediate pressure so that the inspired partial pressure of N\textsubscript{2} (P\textsubscript{IN}N\textsubscript{2}) was lower than the initial P\textsubscript{IN}N\textsubscript{2} (Allen *et al.* 1969, Maio *et al.* 1970, Cooke & Robertson 1974, Horrigan & Waligora 1980, Waligora *et al.* 1983). The staged depressurization approach is enhanced when O\textsubscript{2} concentration is also increased to lessen the impact of hypoxia and to further reduce P\textsubscript{IN}N\textsubscript{2}. However, the initial pressure reduction could transform a subpopulation of tissue micronuclei into “silent” bubbles, so a 60-min PB with a mask was performed before the initial modest reduction in ambient pressure to 10.2 psia (Damato *et al.* 1963, Degner *et al.* 1965, Vann & Torre-Bueno 1984, Waligora *et al.* 1984, Hills 1985).

This protocol that ultimately became the preferred PB for the Shuttle was achieved in 3 steps:

1. Initial 60-min PB by mask, 45 min of which was completed before the Shuttle atmosphere was depressurized from 14.7 to 10.2 psia and the air was enriched to 26.5% O\textsubscript{2} to provide an inspired partial pressure of O\textsubscript{2} (P\textsubscript{IO2}) of 127 mmHg.
2. Minimum stay of 12 hr at this intermediate pressure.
3. In-suit PB before a final depressurization to 4.3 psia, lasting 40 to 75 min depending on the time spent at 10.2 psia.

Figure 1 shows the cumulative fraction of VGE first detected in subjects exposed to 4.3 psia for 4 hr after 3 different PBs. A related figure appears in Waligora *et al.* (1984) (their Figure 12).
All subjects performed EVA-simulation work activities and were ambulatory at 4.3 psia. The solid line that increases (steps) and plateaus quickly to approximately 45% is derived from data from 10 of 22 subjects that had VGE with a mean onset time of 43 ± 43 min. This trial did not include a 1-hr PB before a 12-hr stay at 10.2 psia where subjects breathed 26.5% O₂. The dashed line that plateaus to approximately 50% VGE is derived from the same trial as described above except that it did include a 1-hr PB before the ascent to 10.2 psia. The mean VGE onset time in 18 of 35 subjects with VGE was 105 ± 48 min. Finally, the dashed line that plateaus to approximately 65% VGE was derived from a trial with a 3.5-hr PB and a direct ascent to 4.3 psia. The mean VGE onset time in 15 of 23 subjects with VGE was 115 ± 55 min. The mean VGE onset times were significantly longer (p<0.002) compared with the times from the trial without the 1-hr PB before ascent to 10.2 psia for 12 hr.

![Graph showing cumulative VGE fraction over time at 4.3 psia](image)

**Figure 1.** The onset time for the first detection of VGE was earlier in a trial (Test 2b) where no PB was performed before the first ascent and subsequent 12-hr exposure to 10.2 psia (solid line) compared with the onset time when a 1-hr PB was performed (50% peak, Test 3b) or when there was a direct ascent to 4.3 psia after a 3.5-hr PB (65% peak, Test 2a). Data for Test 3b are from 4 hr of a 6-hr exposure.

The computed decompression dose (described later) was slightly higher in the trial that omitted the initial 1-hr PB, so a high group incidence of VGE was expected. Instead, a rapid onset of VGE was observed in a few subjects, possibly because micronuclei associated with the vascular endothelium transformed into silent bubbles ready to grow and enter the venous circulation after the final depressurization to 4.3 psia. An ascent to only 10.2 psia (3,000 m, 9,750 ft) without utilizing a PB protocol predisposed some subjects to produce VGE shortly after reaching 4.3 psia, even after spending 12 hr at 10.2 psia, with a 40-min PB before the final ascent to 4.3 psia. It is notable that in 5 of the 10 subjects in this trial, VGE was first detected within 30 min at 4.3 psia. VGE was detected in 1 subject after 1 min at 4.3 psia, and the subject had signs and symptoms classified as serious DCS at 65 min. DCS was diagnosed in all 3 trials, with a group incidence of approximately 20% and a mean onset time to first symptoms of approximately 2 hr.
Optimization of the final Shuttle 10.2-psia staged depressurization protocol took months of planning and years of validation. The first critical step was to certify the Shuttle for operations at a reduced pressure with an enriched O_2 atmosphere, as the vehicle was not planned to operate under these conditions. Several interacting variables were evaluated in isolation or in combination: rate of ascent to intermediate pressure, the intermediate pressure itself (equipment cooling issues, Horrigan et al. 1985), the pO_2 and pN_2 at the intermediate pressure (hypoxia and flammability issues, Waligora et al. 1982), length of stay (Damato et al. 1963, Waligora et al. 1983), likelihood of silent bubbles, final suit pressure, duration of EVA, work performed in the suit, final in-suit PB time before final ascent, and balancing the acceptable risk of DCS during EVA with limited treatment options (Adams et al. 1981, Waligora et al. 1984).

The time at 10.2 psia and 26.5% O_2 did not constitute a break in PB because the lengthy exposure to a reduced pN_2 at approximately 7.5 psia continued the denitrogenation process. Astronauts simply donned their suits at 10.2 psia when they were ready and performed a final 40- to 75-min in-suit PB before final depressurization to 4.3 psia, without the need to first repressurize to 14.7 psia. If the time spent at 10.2 psia was expected to be greater than 36 hr, the initial 60-min mask PB at 14.7 psia was omitted. The rationale for this was that any silent bubbles formed during the 15- to 20-min depressurization to 10.2 psia would be reabsorbed given enough time at 10.2 psia. Although this procedure was complicated and had several operational and physiological impacts, it was preferred over the simpler but less efficient 4-hr in-suit PB protocol. The first EVAs that used the Shuttle staged protocol were on STS-41B in February 1984, and the last of the 153 person-EVAs was in 2011 with the retirement of the Shuttle.

b. Skylab

Skylab provided a unique environment in which to conduct studies on adaptation to µG. The atmosphere for Skylab achieved a working balance between risk and reward. The science and medical community accepted an atmosphere of 70% O_2 at 5.0 psia because the Earth-equivalent P_1O_2 would be 150 mmHg, and the risk of atelectasis was minimized because the atmosphere was 30% N_2. Scientists on Earth did not have to provide a hypoxic or hyperoxic environment as part of their ground-based control studies, so µG was the primary experimental variable. No dedicated PB was needed before EVAs from Skylab in spacesuits pressurized to 3.7 psia because the tissues would eventually equilibrate to a computed tissue N_2 partial pressure (P_1N_2) of no more than 1.2 psia, far below the suit pressure. Various restrictions, such as uncomfortable flame-retardant polybenzimidazole clothing, were imposed due to the serious risk of fire in a 70% O_2 atmosphere. However, Skylab was a success, and the need to confront several technical issues early in the mission showed that an effective EVA capability was critical to the success of long-duration missions.

c. Apollo and Gemini

A minimum 3-hr in-suit PB was performed before launch in all NASA programs prior to the Shuttle (Maio et al. 1970). This protocol protected inactive astronauts from DCS after reaching orbit; during ascent, the cabin pressure was reduced from 14.7 psia to 5.0 psia, and the atmosphere was simultaneously enriched to 100% O_2 (Powell et al. 1994a). Although this PB was effective in most cases, 1 astronaut wrote, years after leaving the space program, that he had
Risk of Decompression Sickness (DCS)

Symptoms consistent with DCS while at 5.0 psia. Michael Collins, during Gemini X and later during Apollo 11, believed he had symptoms of pain-only DCS in his left knee that eventually resolved in the 100% O₂ atmosphere as the missions proceeded (Hawkins & Zieglschmid 1975). This was not an unexpected outcome based on previous PB validation trials reported by Maio et al. (1969, 1970). Astronauts on subsequent EVAs from the Apollo spacecraft and Skylab, as well as on moon walks from the Lunar Module, in suits pressurized to 3.7 psia were not at risk for DCS due to denitrogenation during their extended time in the hypobaric and hyperoxic breathing environment.

6. DCS Modeling Evidence

Probability models are critical to the understanding and mitigation of DCS risk. These models are first developed as statistical descriptions of DCS incidence from a given data set and eventually predict DCS incidence effectively over a given boundary of input parameters. Certain DCS models will be described in this section, and Appendix A is provided for a comprehensive summary of DCS model details. Models are typically used to develop potential PB protocols, which are then tested on the ground in hypobaric EVA simulations to ensure that the protocol achieves acceptable DCS risk level. DCS models assess impacts to ground-validated protocols, which are often modified during the transition from research to operations. In these cases, the models are used to ensure that changes to the validation protocol are neutral or in favor of enhanced crew safety. In some cases, DCS probability models, in conjunction with expert opinion, have been used in place of ground testing to accept a PB protocol, which was the case with the Campout PB.

In addition to statistically driven probability models, a decompression dose can also be computed from a biophysical model of bubble growth, such as the maximum size a theoretical bubble can achieve, the rate of growth of the bubble, and the summed volume from a collection of bubbles competing for inert gas (Tikuisis & Gerth 2003, Srinivasan et al. 2003).

a. Tissue Ratio

Fundamental to understanding the P(DCS) in astronauts is to first understand how a tissue ratio (TR) is calculated. The TR is a simple index of decompression dose, first used by Haldane to define the limit to direct ascent for divers at the end of the 19th century. The reader is referred to Stepanek & Webb (2008) for the historical background on the TR.

The TR is the ratio of the computed P₁ N₂ in a theoretical tissue to ambient pressure. Equation 2 defines P₁ N₂, and P₂ is the ambient pressure after depressurization. Prebreathing 100% O₂ or O₂-enriched mixtures before a hypobaric exposure reduces P(DCS), so it is necessary to account for the use of O₂-enriched mixtures as part of the expression for decompression dose. After pN₂ in the breathing mixture changes, such as during a switch from ambient air to a mask supplied with 100% O₂, the pN₂ that is reached in a designated tissue compartment after a specific time is P₁ N₂:

\[ P₁ N₂ = P₀ + (P_a - P₀) (1 - e^{-k t}), \]  

(2)
Risk of Decompression Sickness (DCS)

where \( P1N_2 \) is calculated for the tissue after \( t \) min, \( P_0 \) is the initial \( pN_2 \) in the compartment, \( P_a \) is the ambient \( pN_2 \) in the breathing mixture, and \( t \) is the time at the new \( P_a \) in min. The tissue rate constant \( k \) is equal to \( \ln(2) / t_{1/2} \), where \( t_{1/2} \) is the half-time for \( pN_2 \) in the 360-min compartment. The particular half-time compartment is a statistical construct that optimizes TR as a decompression dose based on the observed dichotomous DCS or VGE outcomes from a collection of trials (Vann et al. 1987). Different half-time compartments reflect the varying rates at which different body tissues take up and eliminate inert gases. For example, fast 5- and 10-min half-time compartments are used to represent the brain and spinal cord, which are highly perfused and rapidly take-up and eliminate inert gases. A long 360-min half-time is associated with long PB times as tested by NASA (Conkin et al. 1996). A shorter half-time combined with long PBs produce low TRs that are not consistent (optimized) with trials that yield significant DCS and VGE incidence. The half-time compartment is simply a surrogate linked to the actual process at the tissue level that dictates the true evolved gas condition.

Equation 3 describes the simple case where \( P_a \) changes instantaneously, a step-change. This form is sufficient in most applications since donning or removing an \( O_2 \) mask changes \( P_a \) within a few breaths. There is also the possibility that \( P_a \) changes over time, such as by breathing air during a long depressurization or by changing the \( N_2 \) content over time at some intermediate pressure. An expanded form of Eq. 3 covers these cases. One novel application is to reduce \( N_2 \) content over time as dictated by the operational time-line such that \( P1N_2 \) is appropriate at the time of suit donning, thus avoiding a final in-suit PB period. This application requires an automated control system to change the breathing atmosphere over time and space within a vehicle that is compatible with enriched \( O_2 \). The cost likely exceeds the rewards with this approach, so it has not been pursued. Finally, Eq. 2 is modified to compute \( P1N_2 \) to account for intervals of exercise during PB. The tissue rate constant \( k \) is defined in terms of \( %VO_2 \) peak during the PB (Conkin et al. 2004).

Equation 3 is one form of the TR as the decompression dose, which approximates the potential volume at an ambient pressure of \( N_2 \) evolved in a unit volume of tissue given that all the available \( N_2 \) at \( P_2 \) has transformed from the dissolved state to the evolved state (Conkin 1994, Conkin et al. 1998):

\[
\text{decompression dose} = \left[ \frac{(P1N_2)}{P_2} - 0.79 \right],
\]

(3)

where decompression dose is 0 at sea level because \( \left[ \frac{(11.6)}{14.7} - 0.79 \right] \) is 0.

The TR is an index of the true decompression dose and is fundamental to other formal expressions of decompression dose as evolved gas. Given an abundance of quality research data, the bottom of the S-shaped curve on a DCS versus TR dose-response curve would be nearly flat over a range of TRs to approximately 1.1. The flat region is an indication that decompression dose must exceed some critical value. The TR is utilitarian and easy to use in statistical regression models to describe DCS and VGE outcomes from combined research trials over a range of TRs. TR, or R-value in NASA terminology, becomes a number that cannot be exceeded. For example, an R-value of 1.65 or less is acceptable for EVA operations in the 4.3 psia EMU from the Shuttle, but this R-value of 1.65 in an EMU does not mean the \( P(\text{DCS}) \) is zero (Conkin et al. 1990, Kumar & Powell 1994).

20
Risk and reward must be balanced to achieve an operational protocol, and finding this balance is as much an art as a science. Operations using the Russian Orlan spacesuit at 5.8 psia result in an R-value of approximately 1.85 to provide a P(DCS) that is the equivalent of the P(DCS) in the EMU; thus, the acceptable R-value (TR) is not an absolute, but is a function of the suit pressure (Conkin et al. 1996, Chadov et al. 1996). The DCS research and operational EVA experience in the Russian space program is too extensive to summarize here (Barer 1995a) and parallels the efforts in the U.S. space program.

b. Statistical and Biophysical Models

Statistical descriptions of DCS and VGE outcomes from hypobaric exposures using logistic regression and survival analysis and biophysical modeling of tissue bubble dynamics have both made significant advances in the last 20 years. The integration of both approaches has produced sophisticated probabilistic models, which are briefly summarized here. Probabilistic modeling requires four items: (1) a data set that contains a dichotomous response variable, i.e., the presence or absence of DCS, and one or more explanatory variables; (2) an expression of decompression dose in terms of explanatory variables; (3) a function, such as the logistic function or Hill equation, which structures the dose model so that the outcome is a calculated P(DCS); and (4) a parameter-estimation routine on a computer that uses maximum likelihood.

Simple descriptions of decompression dose, such as TR or ΔP, approximate the true dose (Weathersby & Homer 1984, Conkin 1994), whereas models about tissue bubble dynamics strive to define the true dose through diffusion-based physics and consideration of mass-balance (Epstein & Plesset 1950, Van Liew & Hlastala 1969, Gernhardt 1991, and more recently Gerth & Vann 1997, Thalmann et al. 1997, Srinivasan et al. 2002, 2003, and Nikolayev 2008). These referenced models, as well as many others, contribute to a single evolving model that describes the P(DCS) in both diving and altitude depressurizations by invoking multiple tissue compartments, multiple finitely diffusible gases, and a distribution of bubble nuclei that begin to grow at different times during depressurization. Other researchers have concentrated just on hypobaric depressurizations (Foster et al. 2000a,b, Kumar et al. 1992, Kumar & Powell 1994, Conkin et al. 1996, Pilmanis et al. 2004, Thompson et al. 2003). Recent advances in probabilistic modeling came through the use of techniques from survival analysis. Weathersby & Gerth (2002) and Tikuisis & Gerth (2003) provided additional details about probabilistic DCS modeling.

Tissue Bubble Dynamics Model (TBDM):

The TBDM is a biophysical model of bubble growth in tissue (Gernhardt 1991) that has been used in the development of decompression protocols for more than 25,000 commercial dives and used by NASA in the development of EVA prebreathe protocols (Gernhardt 2008). In the model, assumed fixed values for several parameters, such as the blood-tissue N\textsubscript{2} partition coefficient, initial radius of micronuclei, N\textsubscript{2} diffusivity between a tissue and bubble, surface tension on a spherical bubble, and tissue bulk modulus, are used to describe the mass balance of tissue and bubble gases for a single growing bubble in a unit volume of tissue (details in Figure 2).
When inputted with the relevant durations, rates, pressures, and gas compositions, the TBDM generates an output called the bubble growth index (BGI), which is the time-varying ratio of bubble radius to an initial 3-µm radius of the bubble nucleus. The BGI for a decompression exposure is calculated over the duration of the exposure, with the peak BGI value typically being used as the primary measure of decompression stress. Although the TBDM accommodates modeling of multiple half-time compartments to reflect the varying rates at which different body tissues take up and eliminate inert gases, the model typically includes only a 360-min theoretical half-time for tissue $N_2$ kinetics when it is used to estimate decompression stress during EVAs.

**Bubble Growth Equation:**

$$\frac{dR}{dt} = -\frac{\alpha D}{h(r,t)} \left[ P_a - vt + \frac{2\gamma}{r} + \frac{4}{3} \pi r^3 M - P_{\text{total}} - P_{\text{metabolic}} \right] + \frac{rv}{3} P_a - vt + \frac{4\gamma}{3} + \frac{8}{3} \pi r^3 M$$

- $r =$ Bubble Radius (cm)
- $t =$ Time (sec)
- $\alpha =$ Gas Solubility ((mL gas)/(mL tissue))
- $D =$ Diffusion Coefficient ($cm^2$/sec)
- $h(r,t) =$ Bubble Film Thickness (cm)
- $P_a =$ Initial Ambient Pressure (dyne/cm$^2$)
- $v =$ Ascent/Descent Rate (dyne/cm$^2$-cm$^3$)
- $\gamma =$ Surface Tension (dyne/cm)
- $M =$ Tissue Modulus of Deformability (dyne/cm$^2$-cm$^3$)
- $P_{\text{total}} =$ Total Inert Gas Tissue Tension (dyne/cm$^2$)
- $P_{\text{metabolic}} =$ Total Metabolic Gas Tissue Tension

**Figure 2.** Tissue Bubble Dynamic Model equation and parameters

A statistical analysis of 6437 laboratory dives (430 DCS cases) compared predictions of the TBDM with the Workman $M$-value and the Hempleman PrT index, with TBDM predictions (BGI) yielding the best log-likelihood and Hosmer-Lemeshow (H-L) goodness-of-fit test results (Gernhardt 1991). BGI also provided significant predictive ability ($p < 0.01$) and goodness-of-fit for DCS (H-L $p=0.35$) and VGE (H-L $p=0.55$) data based on 345 altitude decompression exposures (57 DCS cases, 16.5% DCS, 41.4% VGE), including prebreathe staged decompressions, all with exercise at altitude and including data points at 10.2, 6.0, and 4.3 psi (Abercromby et al. 2008).  

c. **Modeling and Operations**

One reasonable expectation from modeling is that fewer trials, or even no trials, are performed before accepting a variation of a tested protocol if the model computes an acceptable $P$(DCS), $P$(serious DCS), or even $P$(Grade IV VGE). This was the case in a recent decision to accept the campout PB for ISS without direct testing of this variant of the Shuttle 10.2 psi staged PB (Gernhardt 2008). Aside from increasing computational efficiency for complex models,
probabilistic modeling will significantly advance when the link is quantified between evolved
gas in tissue and the perception of pain by the central nervous system (Conkin et al. 1998). An
assumption in modeling is that the outcome variable is known with certainty, which is not the
case (Weathersby et al. 1984, Freiberger et al. 2004, Conkin et al. 2006), and adds an additional
level of uncertainty to probabilistic modeling.

Table 1 shows the DCS incidence from PB protocol ground validation trials compared with the
flight DCS incidence and the modeling predictions that take into account the operational changes
from the ground trial protocol to the in-flight operational PB protocol (Conkin & Powell 2001).
Accepting a new PB protocol without prior ground testing validation is rare, but the ISS campout
protocol was accepted in 2005 based on empirical evidence and modeling analysis. It has been
successfully used from ISS to support over 145 person-EVAs to date.

Table 1. Observed and model-estimated probability of DCS for NASA prebreathe protocols as
of August 1, 2013.

<table>
<thead>
<tr>
<th>Prebreathe Option</th>
<th>Ground Trial Subjects Tested</th>
<th>Ground Trial DCS Incidence (95% CL*)</th>
<th>Model Prediction† P(DCS) (95% CI**)</th>
<th>EVAs using PB Option</th>
<th>Flight DCS Incidence (95% CL*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-hr In-Suit</td>
<td>28</td>
<td>21.40% (9.8-38.0%)</td>
<td>4.60% (2.2-9.4%)</td>
<td>4</td>
<td>0% (0.0-60.0%)</td>
</tr>
<tr>
<td>Campout</td>
<td>--</td>
<td>--</td>
<td>2.80% (1.2-5.9%)</td>
<td>145</td>
<td>0% (0.0-2.7%)</td>
</tr>
<tr>
<td>CEVIS</td>
<td>45</td>
<td>0% (0.0-6.5%)</td>
<td>2.00% (0.4-9.2%)</td>
<td>48</td>
<td>0% (0.0-9.2%)</td>
</tr>
<tr>
<td>ISLE</td>
<td>47</td>
<td>4.20% (0.7-12.8%)</td>
<td>0.30%</td>
<td>16</td>
<td>No 95% CL calculated</td>
</tr>
</tbody>
</table>

*From binomial distribution – one-sided 95% CL
**From regression models that provide 95% CI
†Model predictions include operational prebreathe margin and effects of microgravity.
††Based on option 1 operational prebreathe given a nominal value of 6.8 ml/kg/min.

Existing models can only be extrapolated to the Exploration Atmosphere environment because
the data underlying the model assumptions are based on depressurizations from 14.7 psia. An
example of the application of probabilistic DCS models is provided in Table 2. The simulations
for final in-suit PB times are based on an assumption of equilibrating to an atmosphere of 8.0
psia with 32% O₂ prior to the final in-suit PB. Even with the recent recommendation to adjust to
8.2 psia with 34% O₂, the partial pressure of N₂ remains the same; therefore, the computed
P(DCS) would not change (Norcross et al. 2013).
Table 2. Examples of model-estimated P(DCS) for a simulated lunar mission.*

<table>
<thead>
<tr>
<th>P1N2</th>
<th>PB (min)</th>
<th>TR</th>
<th>P(DCS) (95% CI)</th>
<th>P(VGE)</th>
<th>P(G IV,VGE)</th>
<th>P(serious DCS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.57</td>
<td>0</td>
<td>1.29</td>
<td>0.13 (0-0.30)</td>
<td>0.20</td>
<td>0.19</td>
<td>0.003</td>
</tr>
<tr>
<td>5.57</td>
<td>22</td>
<td>1.25</td>
<td>0.099 (0-0.26)</td>
<td>0.15</td>
<td>0.16</td>
<td>0.002</td>
</tr>
<tr>
<td>5.44</td>
<td>0</td>
<td>1.26</td>
<td>0.10 (0-0.27)</td>
<td>0.17</td>
<td>0.17</td>
<td>0.003</td>
</tr>
<tr>
<td>5.44</td>
<td>22</td>
<td>1.22</td>
<td>0.082 (0-0.21)</td>
<td>0.13</td>
<td>0.14</td>
<td>0.002</td>
</tr>
<tr>
<td>5.44</td>
<td>30</td>
<td>1.19</td>
<td>0.06 (0-0.18)</td>
<td>0.10</td>
<td>0.12</td>
<td>0.0017</td>
</tr>
</tbody>
</table>


* All estimates are extrapolations from statistical models.
Results based on 8-hr EVA with equivalent 1-G ambulation and mild exercise.
EVA after equilibration to 8.0 psia with 32% O2.
# unpublished Grade IV VGE regression from Conkin, n = 549 NASA records.

B. Ground-based Evidence

Validation testing often precedes the implementation of a PB protocol in space operations. The first test of several PB protocols was in August 1982, with DCS reported after a 3.5-hr PB in one subject and a Doppler technician (Conkin et al. 1990, 2003). This was an inauspicious start to the validation of a 3.5-hr PB. A 4-hr PB reduced the incidence of DCS from 42% to 21% and reduced the incidence of VGE from 71% to 46% based on data normalized to a 6-hr exposure to 4.3 psia in men who ambulated as part of their exercise at 4.3 psia (Waligora et al. 1984, Conkin et al. 1990). On April 12, 1981, the Shuttle STS became a reality. The first EVA from the Shuttle was on April 7, 1983, using a 3.5-hr baseline in-suit PB. Only 3 two-person EVAs have been performed from the Shuttle after a 3.5- or 4-hr in-suit PB since April 1983. The 4-hr in-suit PB remained an option throughout the Shuttle program and remains on option on ISS.

The inefficiency of an in-suit PB and the possibility of a break in PB during the transition from an O2 mask to the spacesuit required that NASA validate the staged 10.2 psia protocol in the early 1980s. Variations of similar protocols soon emerged, along with a desire to summarize all the results with a simple decompression dose. In addition to the DCS outcomes, routine ultrasound bubble monitoring provided an unbiased assessment of the decompression dose. The Spencer 0 – IV categorical scale (Spencer 1976, Neuman et al. 1976) was adopted, and the following standard 4-min evaluation scheme to improve bubble detection and grading was implemented at JSC (Adams et al. 1979): a Doppler technician located and optimized an acceptable Doppler ultrasound blood flow signal in the pulmonary artery from a sitting or semi-recumbent subject in an altitude chamber in approximately 15 sec. The subject was then instructed to rhythmically flex each limb three times in sequence, moving all joints in the limb. The movement dislodged small bubbles sequestered in venous capillaries, and the grade of VGE
Risk of Decompression Sickness (DCS)

passing beneath a 5.0- or 2.5-mHz ultrasound wave was assigned by an investigator outside the altitude chamber.

Figure 3 illustrates decompression dose-response curves for DCS and VGE outcomes from 341 exposures to 4.3 psia in altitude chambers at JSC. These subjects breathed 100% O₂ through a mask and were otherwise in a comfortable shirtsleeve environment. The mean exposure time was 4.4 ± 1.3 hr, and subjects ambulated from one exercise station to another. Exercise included cranking and pulling against modest resistance, as well as torquing fixtures to simulate the type and intensity of work performed during a contingency EVA; details are provided in Conkin et al. (2003). At intervals of approximately 15 min, the pulmonary artery was insonated with an ultrasound bubble detector in recumbent subjects. Given enough exposures over a range of decompression doses, a predictive equation for DCS and VGE was created, in this case from the Hill equation. The wide 95% confidence limits for DCS and VGE suggest that factors other than simple decompression dose influence the outcome. There is more to accepting a denitrogenation protocol than just the raw incidence of DCS or VGE. The nature of the symptoms, how the incidence of DCS is related to the intensity of the symptoms (Allen et al. 1971), and the response of individuals to repressurization (Krause & Pilmanis 2000) are as important as the overall incidence of DCS and VGE to a final decision to accept a protocol.

Figure 3. P(DCS) and P(VGE) increase as decompression dose increases. The 95% confidence limits (shorter curves) above and below the best estimate help to visualize uncertainty in the outcome.

Table 3 summarizes DCS and VGE results archived at JSC in the NASA Hypobaric Decompression Sickness Database. Tests conducted for NASA by Brooks Air Force Base (AFB) are not shown here but are available in the Air Force Research Laboratory Altitude Decompression Sickness Research Database archived at Wright-Patterson AFB and available through their website. Operational questions dictated the sequence of testing in Table 3. The
first trials evaluated the 3.5- (Tests 1a and 2a) and then 4-hr in-suit PBs (Tests 3a and 3c), and the subjects in these protocols often “crossed over” to validate the 10.2 psia staged PBs. Several variations of the staged protocol tested the benefit of an initial 60-min PB before ascent to 10.2 psia, different durations at 10.2 psia, and different final in-suit PB times before depressurization to 4.3 psia (Tests 1b, 1c, 1d, 2b, 3b, 3d). Repetitive exposures to 4.3 psia while living at 10.2 psia addressed issues of fatigue and cumulative DCS and VGE risk (Tests 4a through 4f). Cumulative risk was found not to be a concern in repetitive hypobaric depressurizations (Cooke et al. 1975, Conkin et al. 1990, Pilmanis et al. 2002), so repetitive EVAs from the Shuttle were deemed safe. Women were first used at JSC in a trial of a 6-hr PB (Test 5a) and in a novel 10.2-psia staged protocol where the simulated suit pressure was 6.0 psia with 60% O₂. A trial of an 8-hr resting PB (Test 5b) established the benefits of extreme prebreathing, even if not practical from an operational perspective. The influence of high work rate during EVA was evaluated using a row machine (Maio et al. 1970), resulting in two cases being classified as serious DCS in subjects from Test 7a. Exercise intended to counteract deconditioning in space did not influence the subsequent DCS and VGE outcome given that the interval between the exercise and simulated EVA was 16 hr (Tests 8a and 8b; Kumar et al. 1992). The consequences of ambulation before and during an altitude exposure were evaluated at both 6.5 and 4.3 psia in the Argo series, starting with Test 9a and ending with Test 11a. Test 9a included ambulatory controls, and Test 9b included the same subjects but at 6-degree head-down bed rest for 3 days before and during the 3-hr exposure to 6.5 psia without prior PB. The incidence of Grade III plus IV VGE was lower in the bed rest group, and it took longer before Grades III and IV VGE were first detected (Kumar et al. 1993a). Astronauts sometimes fly in commercial airliners or fly a T-38 jet shortly after training in the NBL. Test 10 included a hyperbaric and then a hypobaric exposure to evaluate the consequences of flying after diving under our specific training conditions.
Table 3. Summary of DCS and VGE in tests conducted from 1982-2009.

<table>
<thead>
<tr>
<th>Test</th>
<th>P2 (psia)</th>
<th>Conditions*</th>
<th>Number</th>
<th>Mean age (years)</th>
<th>DCS</th>
<th>VGE (any grade)</th>
<th>VGE (Grade IV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a</td>
<td>4.3</td>
<td>P</td>
<td>11</td>
<td>34.5</td>
<td>4</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>1b</td>
<td>4.3</td>
<td>S</td>
<td>13</td>
<td>32.3</td>
<td>3</td>
<td>11</td>
<td>7</td>
</tr>
<tr>
<td>1c</td>
<td>4.3</td>
<td>S</td>
<td>12</td>
<td>32.0</td>
<td>4</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>1d</td>
<td>4.3</td>
<td>S</td>
<td>3</td>
<td>39.6</td>
<td>2</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>2a</td>
<td>4.3</td>
<td>P</td>
<td>23</td>
<td>31.6</td>
<td>7</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>2b</td>
<td>4.3</td>
<td>S</td>
<td>22</td>
<td>31.5</td>
<td>6†</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>3a</td>
<td>4.3</td>
<td>P</td>
<td>28</td>
<td>31.0</td>
<td>6</td>
<td>13</td>
<td>11</td>
</tr>
<tr>
<td>3b</td>
<td>4.3</td>
<td>P,S</td>
<td>35</td>
<td>30.1</td>
<td>8</td>
<td>20</td>
<td>8</td>
</tr>
<tr>
<td>3c</td>
<td>4.3</td>
<td>P</td>
<td>14</td>
<td>32.5</td>
<td>3</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>3d</td>
<td>4.3</td>
<td>P,S</td>
<td>12</td>
<td>28.5</td>
<td>2</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>4a</td>
<td>4.3</td>
<td>P,S</td>
<td>12</td>
<td>30.1</td>
<td>1</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>4b</td>
<td>4.3</td>
<td>P,S</td>
<td>12</td>
<td>30.1</td>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>4c</td>
<td>4.3</td>
<td>P,S</td>
<td>12</td>
<td>30.1</td>
<td>0</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>4d</td>
<td>4.3</td>
<td>P,S</td>
<td>12</td>
<td>30.1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4e</td>
<td>4.3</td>
<td>P,S</td>
<td>12</td>
<td>30.1</td>
<td>0</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>4f</td>
<td>4.3</td>
<td>P,S</td>
<td>12</td>
<td>30.1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5a</td>
<td>4.3</td>
<td>P</td>
<td>19</td>
<td>31.5</td>
<td>4</td>
<td>11</td>
<td>4</td>
</tr>
<tr>
<td>5b</td>
<td>4.3</td>
<td>P</td>
<td>11</td>
<td>32.0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>6.0</td>
<td>S</td>
<td>15</td>
<td>32.9</td>
<td>1</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>7a</td>
<td>6.5</td>
<td>direct ascent</td>
<td>11</td>
<td>28.2</td>
<td>4††</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>7b</td>
<td>6.5</td>
<td>direct ascent</td>
<td>11</td>
<td>28.2</td>
<td>2</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>8a</td>
<td>6.5</td>
<td>direct ascent</td>
<td>29</td>
<td>32.5</td>
<td>7</td>
<td>20</td>
<td>13</td>
</tr>
<tr>
<td>8b</td>
<td>6.5</td>
<td>direct ascent</td>
<td>30</td>
<td>32.6</td>
<td>10†</td>
<td>22</td>
<td>17</td>
</tr>
<tr>
<td>9a</td>
<td>6.5</td>
<td>direct ascent</td>
<td>15</td>
<td>32.1</td>
<td>1</td>
<td>12</td>
<td>7</td>
</tr>
<tr>
<td>9b</td>
<td>6.5</td>
<td>A</td>
<td>14</td>
<td>33.8</td>
<td>2†</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>9c</td>
<td>4.3</td>
<td>A</td>
<td>9</td>
<td>34.8</td>
<td>3</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>9d</td>
<td>4.3</td>
<td>A</td>
<td>6</td>
<td>36.4</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>9e</td>
<td>4.3</td>
<td>E,A</td>
<td>7</td>
<td>34.6</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>10.1</td>
<td>FAD</td>
<td>14</td>
<td>31.7</td>
<td>1</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>11a</td>
<td>4.3</td>
<td>P,A</td>
<td>16</td>
<td>33.2</td>
<td>3</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>11b</td>
<td>6.5</td>
<td>direct ascent</td>
<td>1</td>
<td>39.5</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Phase I</td>
<td>4.3</td>
<td>P,E,S,A</td>
<td>33</td>
<td>29.1</td>
<td>9</td>
<td>23</td>
<td>2</td>
</tr>
<tr>
<td>Phase II</td>
<td>4.3</td>
<td>P,E,S,A</td>
<td>35</td>
<td>31.7</td>
<td>0</td>
<td>14</td>
<td>3</td>
</tr>
<tr>
<td>Phase III</td>
<td>4.3</td>
<td>P,E,S,A</td>
<td>8</td>
<td>29.9</td>
<td>2†</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Phase IV</td>
<td>4.3</td>
<td>P,E,S,A</td>
<td>44</td>
<td>30.1</td>
<td>8</td>
<td>23</td>
<td>7</td>
</tr>
<tr>
<td>Phase V-1</td>
<td>4.3</td>
<td>P,E,A</td>
<td>7</td>
<td>31.5</td>
<td>3</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Phase V-2</td>
<td>4.3</td>
<td>P,E,A</td>
<td>1</td>
<td>39.2</td>
<td>1†</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Phase V-3</td>
<td>4.3</td>
<td>P,E,A</td>
<td>38</td>
<td>36.9</td>
<td>7</td>
<td>25</td>
<td>5</td>
</tr>
<tr>
<td>Phase V-4</td>
<td>4.3</td>
<td>P,E,A</td>
<td>3</td>
<td>31.5</td>
<td>3</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Phase V-5</td>
<td>4.3</td>
<td>P,E,S,A</td>
<td>37</td>
<td>32.3</td>
<td>2</td>
<td>14</td>
<td>8</td>
</tr>
</tbody>
</table>

*Conditions:  P, some PB occurred before ascent; S, a portion of the PB was spent at 10.2 psia breathing 26.5% O2; A, subjects were “adynamic” (no ambulation before or during the altitude exposure); E, a prescribed exercise was performed during some interval of the PB; FAD, flying after diving.
† One case was classified as Type II DCS; †† Two cases were classified as Type II DCS.
As part of the NASA Prebreathe Reduction Program (PRP), several trials evaluated the benefits of different exercise regimens during PB: short and intense, long and mild, and combinations of the two. The goal was to combine known factors that reduce the P(DCS), such as exercise and adynamia, with representative EVA work simulations using a PB protocol for ISS construction and maintenance. Avoiding ambulation during PB and at altitude does reduce the incidence of DCS and VGE in the lower body, so adynamia is included in all current validation testing as an analog to working in μG (Powell et al. 1992, Conkin & Powell 2001, Vann & Gerth 1997), although there are contrary observations (Balldin et al. 2002). In PRP Phases I through IV, researchers evaluated the influence of combined intense dual-cycle ergometry for 10 min with additional low-intensity exercise on the DCS and VGE outcome. After completing the initial 50 min of PB at site pressure, the subjects were depressurized to 10.2 psia over 30 min while still breathing 100% O₂, and 30 min were then spent at 10.2 psia breathing 26.5% O₂ to reproduce the suit donning conditions in the ISS airlock. Then, 100% O₂ was reintroduced into their masks and they were repressurized to site pressure within 5 min to complete the final 35 min of PB. After a 150 min total PB time, a final depressurization from site pressure to 4.3 psia was completed in 30 min, and the subjects simulated EVA work tasks at 4.3 psia for 4 hr. Phase II met the accept conditions, as described earlier, for an ISS PB and became the operational Exercise PB protocol. In PRP trials from Phases V-1 to V-4, researchers evaluated whether mild exercise that could be performed during an in-suit PB at 14.7 psia would be effective, but none met the prospective acceptable conditions. The final trials in this series (Phase V-5) extended mild exercise and the total PB time to 190 min, which included a 30-min suit donning step at 10.2 psia, and became the operational ISLE PB protocol. Instead of referencing publications over a period of 30 years that cover the specifics of all trials, the reader can find details in Conkin et al. (2003, 2004) for trials from 1a to Phase IV. Details from Phases V-1 to V-5 are provided in Gernhardt & Pollock (2006).

1. Master Logic Diagram

The goal of most ground-based research studies was to determine if a given operational PB protocol would reduce the P(DCS) to acceptable levels. Even under this operational research paradigm, where certain risk factors for DCS were not systematically evaluated, a growing body of evidence accumulated to describe certain factors that contribute to DCS. Known factors are shown in Figure 4, the Master Logic Diagram, which describes the various factors that contribute to DCS likelihood and consequence. Understanding of these factors is a result of variations of ground-based chamber studies of PB protocols intended to protect astronauts from DCS during EVA.
Figure 4. Understanding and managing DCS has many components, as seen in the Master Logic Diagram for DCS.

2. Inadequate Denitrogenation

Much of the information about denitrogenation and hypobaric DCS that was learned during and shortly after World War II (WW II) is available on the pages of Fulton’s 1951 book (Bateman 1951, Jones 1951), with additional information provided in the 4th edition of Fundamentals of Aerospace Medicine (Stepanek & Webb 2008) and The Proceedings of the 1990 Hypobaric Decompression Sickness Workshop (Pilmanis 1992). The advent of Doppler ultrasound bubble detection technology in the 1970s provided a useful tool with which to understand DCS. Clearly, denitrogenation protocols are effective in reducing the P(DCS) and the severity of symptoms, as well as the potential for venous gas emboli (VGE) and arterial gas emboli (AGE). After denitrogenation, which typically involves oxygen (O₂) prebreathing, an astronaut has a small amount of tissue nitrogen (N₂) to manage. Once the astronaut depressurizes to a low-pressure spacesuit, the volume expansion (Boyle’s Law) of this remaining N₂ at the new lower pressure is concerning.

One major contribution to how much N₂ stays in the body after a PB is body fat content. It is important to define the minimum PB time that protects the greatest number of EVA astronauts,
Risk of Decompression Sickness (DCS)

regardless of whether they are male or female and given a reasonable range of body types. It is important to keep the PB procedure simple and to balance the risk of DCS with available treatment resources (McIver et al. 1967). Risk is defined as the P(DCS) and the consequence of DCS, and because the consequence of a serious case of DCS in space is high, the P(Serious DCS) must be very low to achieve an acceptable operational risk.

Males and females each display a wide range of body types. A brief generic comparison using gender illustrates that no two people have the same quality or quantity of N\textsubscript{2} elimination (washout) and uptake (washin). Table 4 shows the estimated volume of N\textsubscript{2} dissolved in lean and fat tissues in a representative male and female. The total volume of N\textsubscript{2} is slightly higher in women than men, given an N\textsubscript{2} solubility coefficient of 0.0146 ml (STPD) N\textsubscript{2}/ml tissue $\times$ ATM N\textsubscript{2} in lean (aqueous) tissue and 0.0615 ml N\textsubscript{2}/ml tissue $\times$ ATM N\textsubscript{2} in fat (lipid) tissue, as well as the other information in the table.

Table 4. Estimated N\textsubscript{2} content by gender.

<table>
<thead>
<tr>
<th>gender</th>
<th>wt (kg)</th>
<th>body fat % (% total wt)</th>
<th>fat mass (kg)</th>
<th>N\textsubscript{2} volume in fat tissue (ml)*</th>
<th>lean mass (kg)</th>
<th>N\textsubscript{2} volume in lean tissue (ml)</th>
<th>total N\textsubscript{2} volume (ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>male</td>
<td>75</td>
<td>10</td>
<td>7.5</td>
<td>405</td>
<td>67.5</td>
<td>778</td>
<td>1183</td>
</tr>
<tr>
<td>female</td>
<td>60</td>
<td>25</td>
<td>15.0</td>
<td>809</td>
<td>45.0</td>
<td>519</td>
<td>1328</td>
</tr>
</tbody>
</table>

* Density of fat = 0.9 g/ml, density of lean tissue = 1.1 g/ml, partial pressure of N\textsubscript{2} = 0.79 ATA in breathing air, and total body weight was not reduced to compensate for the weight of inert bone.

Apparent in this example is that the amount of N\textsubscript{2} in fat tissues of women is twice that of men and that the amount of N\textsubscript{2} in lean tissues of men is slightly greater than that in women. Given enough PB time, the same total volume of N\textsubscript{2} would be removed from men and women. However, PB time is always limited, so the kinetics of N\textsubscript{2} elimination and the relative contributions of N\textsubscript{2} from the fat and lean tissues during a limited PB must be considered. In this example, a large amount of N\textsubscript{2} would quickly be eliminated from the well-perfused and large lean tissue reservoir in men, with a lesser amount of N\textsubscript{2} coming from the poorly perfused fat depot that is smaller than that in women. The poorly perfused fat contributes some N\textsubscript{2} throughout the PB but is likely responsible for the long tail of a typical N\textsubscript{2} elimination curve. Females also provide a large amount of N\textsubscript{2} initially removed from a well-perfused but smaller lean tissue reservoir, with a greater amount of N\textsubscript{2} than that in men, which is derived from a poorly perfused fat depot that is larger than that in men. The poorly perfused fat tissue has a 5-fold greater affinity for N\textsubscript{2} than does the well-perfused lean tissue. As a result, a large amount of N\textsubscript{2} is available from fat tissue in women and the N\textsubscript{2} slowly leaves the body during PB, such that an even longer tail on a typical N\textsubscript{2} elimination curve would be expected for women compared with men.

It is important to define the minimum PB time that protects the greatest number of EVA astronauts, regardless of whether they are male or female and given a reasonable range of body types. It is important to keep the PB procedure simple and to balance the risk of DCS with available treatment resources (McIver et al. 1967). Risk is defined as the P(DCS) and the consequence of DCS, and because the consequence of a serious case of DCS in space is high, the P(Serious DCS) must be very low to achieve an acceptable operational risk.
Risk of Decompression Sickness (DCS)

Air break during prebreathe:

Various methods to preserve the quality of and confidence in the PB during the transition from the mask to the suit were evaluated at JSC, and all were found to be inadequate. In effect, the inability to avoid a potentially long air break in PB at 14.7 psia and ignorance of the consequences of an air break during PB were responsible for the development of the staged denitrogenation protocols on the Shuttle and ISS (Horrigan & Waligora 1980, Powell et al. 1994a). The few research studies that exist about PB breaks are listed here in chronological order: Clarke et al. (1945), Bateman (1951), Cooke (1976), Adams et al. (1977), Horrigan et al. (1979), Dixon et al. (1980), Barer et al. (1983), and, most recently, Pilmanis et al. (2010).

A lengthy break in PB is an operational reality that could compromise an otherwise safe denitrogenation procedure and jeopardize a scheduled EVA. The NASA Aeromedical Flight Rules define O₂ payback time based on the location and duration of a simple air break during a PB. Payback time is the number of minutes of additional PB time needed to compensate for an interruption in the original PB time. For air breaks during resting PB, the payback time on 100% O₂ is 2 times the duration of the air break and 4 times the duration if the air break occurs early in the exercise PB protocol for the ISS. A break in PB longer than 10 min requires that the PB be repeated from the start or that the crew switch to an alternative PB protocol. A notable case of a complicated break in PB occurred during the preparations for the second of three EVAs on STS-129. A mechanical problem in the airlock control panel on the ISS occurred approximately 2 hr into the sleep period of the campout PB. This failure initiated a repressurization of the airlock. There was no reasonable recovery from this air break due to the time needed to reconfigure the airlock operations. The decision was made to switch to the exercise PB protocol, which was completed the following day and preserved the original scheduling of the second EVA.

Estimates for PB payback time have ranged from 1 (Cooke 1976) to 35 times (Adams et al. 1977) the duration of the air break. Unfortunately, no published results exist that can be confidently applied to NASA operations. There are simply no data on payback time if PB is interrupted during exercise. Simple rules for PB compensation after an air break are desirable for space EVA operations, but no two people have identical N₂ uptake and elimination kinetics, and in reality, the duration of the break, the point at which the interruption in the PB occurred, and the remaining amount of PB time are infinitely variable. Breathing 1 ATA of O₂ is known to decrease cardiac output and to increase peripheral vascular resistance by increasing vasoconstriction (Andersen & Hillestad 1970, Anderson et al. 1991). It is reasonable to suppose asymmetrical N₂ kinetics as a consequence of an air break. It is also reasonable to suppose that there is a change in the size distribution of tissue micronuclei as a function of the O₂ window during the PB (Van Liew et al. 1993), and the size distribution is influenced by air breaks. Thus, simple payback rules may not suffice under all conditions, and a quantitative approach to assessing payback time is a goal for the future (Conkin 2011). Data from Pilmanis et al. (2010) showed that a 10-min air break occurring 30 min into a 60-min PB prior to a 4.37-psia exposure did reduce the mean time to onset of symptoms and did increase the DCS incidence at 1 hr compared with controls.
Hypobaric ascent limit:

The need for high-altitude bombing during WW II and the rapid advancement in jet engine development after the war put aviators at risk for DCS, hypoxia, and hypothermia until pressurized and air-conditioned aircraft cabins became common. Before these technical advances occurred, researchers in Canada and the U.S. characterized DCS, mostly with young airmen in training, using hypobaric chambers (Fulton 1951, Adler 1964, Fryer & Roxburgh 1965). It was quickly realized that the altitude attained, the time spent at altitude, and exercise at altitude increased the risk of DCS, both pain-only DCS and serious DCS linked to reactions in the cardiovascular and nervous systems (Conkin 2001, Conkin et al. 2002). Never again will such provocative testing be performed, and “modelers” of DCS must be content with these data to define the upper range of dose-response curves.

Denitrogenation with enriched O₂ mixtures dramatically reduced both pain-only and serious DCS, and most fit young men could tolerate a degree of depressurization even without the benefit of a PB. During the war years, the criteria for a successful ascent centered around having enough time to perform the mission before DCS symptoms became debilitating. Under these extreme conditions, ascents to between 6,096 and 7,620 m (20,000 and 25,000 ft) were acceptable in most operational settings. Several studies were initiated to identify and then screen out personnel who were potential “weak links” as a means to reduce the impact of DCS on the mission. These efforts were abandoned as ineffective and costly but highlighted the reality of between- and within-subject variability in DCS. As the interest in aviator DCS increased after WW II, primarily through the United States Air Force (USAF) and NASA, a systematic approach led to a better understanding of hypobaric ascent limitations. Additionally, a shift in thinking from “tolerable” symptoms to the first onset of mild symptoms reduced the threshold altitude for DCS.

Each year, millions of people on commercial flights are quickly exposed to an altitude between 1,829 and 2,438 m (6,000 and 8,000 ft) for long periods. Most barophysiologists would agree that a rapid ascent to 3048 m (10,000 ft) is without significant risk of DCS, but hypoxia soon limits useful physical activity. The use of enriched O₂ at higher altitudes confounds the basic question about the DCS limit associated with direct ascent (Webb & Pilmanis 1993). In addition to defining the threshold of evolved gas and the interaction of the evolved gas with living tissues that produce symptoms, there are practical reasons to define a hypobaric ascent limit. Prebreathing takes time and resources, and a spacesuit pressurized greater than the lowest pressure sufficient to cause venous gas emboli (VGE) and DCS could be an option to eliminate the risk of DCS (Flugel et al. 1984).

Work to define the threshold for a no PB spacesuit suggests that a 4,420-m (14,500 ft) altitude is close to a no-DCS ascent, with VGE still produced at an altitude of 3,505 m (11,500 ft) (Conkin et al. 1990). Webb et al. (1989) showed that a spacesuit at 9.5 psia (11,500 ft) prevented DCS during 5 repeated exposures in 22 subjects. There is some threshold below which the gas that is evolved after depressurization is insufficient to elicit symptoms, even if it is difficult to establish this without exception. Table 5, modified from Conkin et al. (1990), lists hypobaric exposure pressures and the associated DCS and VGE incidence.
### Table 5. Tests to find threshold altitudes for DCS and VGE.

<table>
<thead>
<tr>
<th>P1N₂ / P2 (psia)</th>
<th>DCS cases / n</th>
<th>VGE cases / n</th>
<th>reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.49, day 1 of 3</td>
<td>7.8</td>
<td>2 / 64 = 3.0%</td>
<td>28 / 64 = 43%</td>
</tr>
<tr>
<td>1.43, day 2 of 3</td>
<td>7.8</td>
<td>2 / 62 = 3.0%</td>
<td>29 / 62 = 46%</td>
</tr>
<tr>
<td>1.42, day 3 of 3</td>
<td>7.8</td>
<td>1 / 60 = 1.6%</td>
<td>25 / 60 = 41%</td>
</tr>
<tr>
<td>1.40</td>
<td>8.3</td>
<td>1 / 31 = 3.2%</td>
<td>8 / 31 = 26%</td>
</tr>
<tr>
<td>1.36</td>
<td>8.5</td>
<td>0 / 9 = 0%</td>
<td>3 / 9 = 33%</td>
</tr>
<tr>
<td>1.29</td>
<td>9.0</td>
<td>0 / 16 = 0%</td>
<td>7 / 16 = 43%</td>
</tr>
<tr>
<td>1.22</td>
<td>9.5</td>
<td>0 / 6 = 0%</td>
<td>1 / 6 = 17%</td>
</tr>
<tr>
<td>1.22</td>
<td>9.5</td>
<td>0 / 31 = 0%</td>
<td>8 / 31 = 26%</td>
</tr>
<tr>
<td>1.22, day 1 of 5</td>
<td>9.5</td>
<td>0 / 23 = 0%</td>
<td>0 / 23 = 0%</td>
</tr>
<tr>
<td>1.11, day 2 of 5</td>
<td>9.5</td>
<td>0 / 22 = 0%</td>
<td>0 / 22 = 0%</td>
</tr>
<tr>
<td>1.10, day 3 of 5</td>
<td>9.5</td>
<td>0 / 22 = 0%</td>
<td>0 / 22 = 0%</td>
</tr>
<tr>
<td>1.10, day 4 of 5</td>
<td>9.5</td>
<td>0 / 22 = 0%</td>
<td>0 / 22 = 0%</td>
</tr>
<tr>
<td>1.10, day 5 of 5</td>
<td>9.5</td>
<td>0 / 22 = 0%</td>
<td>0 / 22 = 0%</td>
</tr>
<tr>
<td>1.16</td>
<td>10.0</td>
<td>0 / 8 = 0%</td>
<td>2 / 8 = 25%</td>
</tr>
</tbody>
</table>

*USAF pilot studies using subjects with a history of DCS and VGE.

Kumar et al. (1990) and Webb et al. (1998) summarized the information in Table 1 and other information about altitude threshold, but they came to different conclusions. Kumar stressed that any threshold for symptoms is conditional on other factors, with his lowest conditional threshold defined as a 3,353-m (11,000 ft) altitude. Webb reported a DCS incidence of approximately 5% for an altitude of 6,096 m (20,000 ft). Probing for the lowest decompression dose to elicit symptoms is a difficult task, as there are always exceptions to the rule (Rudge 1990b, Voge 1989).

3. Activity During EVA

No single variable, other than O₂ PB time, has more of an impact on the P(DCS) than exercise at altitude. Cook (1951) summarized the importance of exercise at altitude as a factor associated
with an increase in the incidence and severity of DCS, as well as a shortened latency time to the first report of DCS. One can limit the P(DCS) at a given suit pressure by limiting exercise during EVA, but this is impractical in most scenarios because astronauts are performing physical tasks during an EVA. The general approach is to provide sufficient PB so that the type, intensity, and duration of EVA work are not considerations. Ambulation that stresses the knees and ankles on the surface of the moon or Mars is expected to increase the risk of DCS for any PB protocol that otherwise performed well in µG (Conkin et al. 1987, Conkin et al. 2001, Webb et al. 2010).

Figure 5 is a classic presentation of the importance of exercise type and intensity toward the P(DCS). The figure is redrawn from Henry (1956). It shows the rate of DCS as a function of lower-body exercise intensity during a stair-step challenge.

![Figure 5](image_url)

**Figure 5.** The rate of DCS as a result of exercise after an ascent to 3.0 psia without PB. Standard exercise was 10 step-ups on a 9-in stool in 30 sec, repeated at 5-min intervals.

4. **Exercise Effects on Micronuclei**

The previous discussion focused on reducing the amount of tissue N$_2$ to limit bubble growth, the classic Haldanean approach, but an emerging area of DCS prevention is to also hinder the transformation of tissue micronuclei into growing bubbles (Tikuisis & Gerth 2003, Blatteau et al. 2006). The presence of gaseous micronuclei in the tissues permits DCS under modest depressurizations (Weathersby et al. 1982). Information about and evidence for tissue micronuclei are primarily derived from indirect observations. One consistent inference from these studies is that normal activity establishes a size distribution of micronuclei within tissues, which can then be modified by changing the type, timing, and intensity of activity.

If micronuclei are considered and if the results from research on DCS are then applied to astronauts who perform EVAs, then walking in an altitude chamber is not a reasonable analog to
EVA or “space walking” (Powell et al. 1992, Powell et al. 1993, Vann & Gerth 1997). Exercise during depressurization increases the risk of DCS, generally in the limb performing the exercise (Conkin et al. 1987, Cooke 1951, Henry 1956, Krutz & Dixon 1987). Walking is such a natural event that, in research on DCS, it is frequently ignored as being exercise. This simple and ubiquitous act has new relevance as humans venture into space and when they ambulate on the moon and later Mars, especially as it relates to the risk of DCS. Calling an EVA in μG from the Shuttle or ISS a ‘spacewalk’ is a misnomer. Astronauts do not ambulate in the conventional sense but only anchor their legs to a stable structure so that the upper body can perform some task. Powell coined the term “adynamia” to characterize the lack of movement and, therefore, the lack of dynamic forces in the lower body (lower body adynamia) over several days of adaptation to μG and during EVAs (Powell et al. 1994, 1995, Kumar et al. 1993a, Conkin & Powell 2001).

The fundamental premise of adynamia is the control of nucleation processes within tissues and fluids. In the absence of supersaturation, the spontaneous rate of nucleation is inconsequential when micronuclei on the order of microns in radius are considered. However, the number or distribution of micronucleus sizes can be influenced before supersaturation exists when mechanical energy is added to the system. It is notable that subjects who performed brief but vigorous dual-cycle (arms and legs) ergometry at the start of an exercise PB showed earlier VGE onset compared with those who performed the ergometry approximately 15 min into the start of the PB (Conkin et al. 2004). A 15-min delay in starting the ergometry in a 150-min total PB time delayed the VGE onset time in research subjects during a subsequent exposure to 4.3 psia. Astronauts always perform EVAs in pairs. Thus, astronauts who use the Exercise PB protocol start the PB at the same time, but someone must go first because there is only one leg ergometer on the ISS dedicated to this protocol.

Violent muscular contractions in bullfrogs before a hypobaric exposure (Whitaker et al. 1945) were associated with bubble formation in the resting animals while at altitude. The number of bubbles was reduced if the frogs were allowed to recover for as long as 1 hr after electrical stimulations. The authors offered 2 explanations for this finding: a short-lived local increase in carbon dioxide (CO₂) that facilitated bubble growth at altitude, or the inception of micronuclei or some other short-lived entities that would later facilitate the growth of bubbles at altitude. This same concept was tested in humans (Dervay et al. 2002) when 20 subjects were exposed to 6.2 psia on 3 separate and random occasions without the confounding of PB or any exercise at altitude during a 2-hr exposure. Each subject performed 150 deep knee flexes in 10 min either 2 hr, 1 hr, or just before ascent, with the remaining time spent adynamic in a chair. It was hypothesized that exercise before decompression would generate a population of some entity (micronuclei, macronuclei, vapor-filled cavities trapped on vascular endothelium, or an increase in the concentration of CO₂) that would diminish in size or concentration given enough time before ascent. The investigators used subsequent VGE information to indirectly test this hypothesis. They observed that intense lower-body activity just before the altitude exposure did cause more VGE to appear and caused them to appear earlier than when exercise was performed earlier. The critical observation was that the predisposing factor(s) diminished with time while subjects sat quietly in a chair before the ascent.
Risk of Decompression Sickness (DCS)

If DCS outcome is related only to tissue N$_2$ supersaturation, then perhaps the decrease in P(DCS) tracks the decrease in computed supersaturation. If the relationship is not a mirror image, then perhaps factors other than N$_2$ supersaturation are co-responsible. The dashed line in Fig. 3 is from the natural logarithm transformation of the exponential decay in a 360-min half-time compartment normalized by dividing the initial tissue N$_2$ pressure by 11.6 psia, the ambient pN$_2$ at sea level. The solid curve is the same transformation applied to the P(DCS) from a survival model (Conkin et al. 1996) evaluated over 6 hr of PB given that the person performed mild exercise at 4.3 psia for 4 hr while breathing 100% O$_2$ through a mask. Other factors that dictate the DCS outcome must exist besides tissue N$_2$ supersaturation or the 2 plots would look similar. If DCS outcome is a complex competition between the potential for evolved gas and the transformation of micronuclei into bubbles, it might be expected that the curves for log[P(DCS)] and log(normalized N$_2$ pressure) would diverge over a range of PB times.

The physics of micronucleus stability, creation, size distribution, absolute numbers in tissues, and transformation into growing bubbles for a given N$_2$ supersaturation must be complex (Van Liew & Raychaudhuri 1997, Van Liew 1998, Van Liew & Conkin 2007). One could hypothesize that only a few large-radius micronuclei could be absorbed during a short 100% O$_2$ PB and that more large- and small-radius micronuclei are absorbed after more than 90 min of PB. There would come a point during a long PB where fewer and smaller-radius micronuclei exist to subsequently transform into growing bubbles under the prevailing reduced N$_2$ supersaturation, as suggested by the rapid decrease in ln[P(DCS)] after 3 hr of PB in the survival model (Figure 6). The reality of bubble growth in tissue is that it is not just the absolute potential for evolved gas, as reflected in an exponential washout curve, but it is a competition between the potential for available gas and the population of micronuclei that are available to accept the excess gas and transform into growing bubbles. The acceptance of this excess gas occurs through simple diffusion, but that is the only simple statement possible.

Figure 6. Change in computed tissue N$_2$ pressure (dashed curve) and the P(DCS) (solid curve) as a function of PB time under conditions of the simulation described in the text.
The classic soda-bottle analogy of bubbles in the body illustrates the physical consequence of depressurization, but emerging science suggests that activation of various stress-induced biomolecules before, during, or after depressurization will influence the DCS and VGE outcomes (Dujić et al. 2006, Valic et al. 2007). Astronauts routinely take aspirin and other pharmacological agents to manage the stress and discomforts of space flight and EVAs, which may influence the DCS and VGE outcomes. The large surface area of the vascular endothelium and its interaction with stress-induced biomolecules offers an opportunity to understand how excess intracellular dissolved gas actually becomes extracellular evolved gas bubbles that are then relocated to the lungs (Wisloff et al. 2004).

5. Duration of EVA

The evolution of gas in tissue is a time-dependent process. Nims (1951) systematically describes the time-dependent process in the development of his theoretical model to describe aviator DCS. Gas evolution has a lag phase, a growth phase, and finally a recovery phase if the EVA continues since tissue and bubble N₂ continues to be removed while breathing 100% O₂ during the EVA. One can limit the P(DCS) at a given suit pressure by limiting the EVA exposure time, but this is impractical in most applications. The general approach is to provide sufficient PB so that EVA duration is not a consideration.

Figure 7 shows the distribution of symptom failure times from denitrogenation protocols that are considered conservative, based on NASA PB validations. Symptom failure times were generally 75 to 175 min in these studies, with fewer cases appearing in minutes and others at 6 hrs. There is a period during any EVA, approximately 3 hrs, after which the likelihood is small that DCS will be reported. Again, this is attributed to the continued removal of N₂ during the course of an EVA.
6. Physiological Predisposition and Risk of DCS

It has been observed that some divers and aviators are particularly resistant or susceptible to DCS and VGE (Weathersby 1989, Kumar et al. 1992, Webb et al. 2005). Depressurization schedules developed to protect the most susceptible individuals are then ultra-safe for the resistant individuals and are therefore not very efficient. Thus, there is a long history of persistent efforts to identify those who are susceptible and to identify the physiological and anatomical factors associated, as either a cause or a correlate, with susceptibility (Allen et al. 1971). Selection schemes, except for natural selection, have not developed past the conceptual stage primarily because prospective, well-controlled studies with adequate sample sizes are expensive.

Table 6 lists examples of factors associated with the risk of DCS and the associated references. Any global conclusions on individual factors are confounded by inconsistencies in the DCS mitigation strategy (primarily PB duration) and decompression dose and duration. Law and Watkins (2010) reviewed literature on individual susceptibility to DCS but provided no additional recommendations for astronaut screening and did not refute the current practice of eliminating astronaut candidates due to flow-significant atrial septal defects.

Figure 7. Histogram time distribution of 216 symptoms in 119 cases of DCS. The distribution is skewed right, with the largest number of DCS reports occurring approximately 120 min into the exposures.
Table 6. Individual Factors Associated with Risk of DCS and VGE.

<table>
<thead>
<tr>
<th>Factors Associated with Risk of DCS and VGE</th>
<th>Some Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFO</td>
<td>Saary &amp; Gray 2001, Foster et al. 2003</td>
</tr>
<tr>
<td>Menstrual Cycle Time</td>
<td>Rudge 1990a, Webb et al. 2003</td>
</tr>
<tr>
<td>Body Fat</td>
<td>Webb et al. 2003, Webb et al. 2005</td>
</tr>
<tr>
<td>Hydration Status</td>
<td>Fahlman &amp; Dromsky 2006</td>
</tr>
</tbody>
</table>

One challenge in understanding the contribution of these factors to DCS and VGE outcomes is that all are part of the whole, and it is difficult to isolate the contribution of one factor. In reality, DCS and VGE outcomes are multifactorial and confounded by many factors, particularly the decompression dose (Kumar et al. 1993).

A practical approach, given a large sample of quality research results, is to perform a multivariate statistical analysis in which the uniqueness of each trial becomes part of the reason, along with other explanatory variables, for the outcome. In other words, a multivariate analysis, such as logistic regression or survival analysis, identifies and controls for confounding and interacting variables so that a better interpretation of the outcome is possible (Conkin 1994, Kumar & Powell 1994). Although a multivariate analysis with large numbers of quality research data with an appropriate range of explanatory variables is necessary to assign the appropriate contribution to an explanatory variable, in general, this approach has not been used and contributes to contradiction and confusion in the literature.

With limited objective data to support specific recommendations for astronaut selection and preparation, we are left with suggesting that an astronaut should be adequately hydrated prior to EVA and that increased aerobic fitness and lower body fat levels may contribute slightly to decreased DCS risk.

7. Relationship Between VGE and Hypobaric DCS

Since silent bubbles were associated with modest hyperbaric and hypobaric exposures, there has been a vigorous debate about the value of VGE detected in the pulmonary artery or other veins in predicting subsequent DCS outcomes (Nishi 1993). The fact that bubbles are present without overt symptoms suggests that, at best, the presence of VGE is a necessary but not sufficient condition for DCS, and relationships between the two are correlative as opposed to cause-and-effect. Correlative relationships differ from one study to the next depending on many factors, such as the decompression dose and the type of breathing gas (Webb & Pilmanis 1993, Pilmanis et al. 2003), the type of ultrasound equipment, training of the Doppler technician, and the methods used to quantify the Doppler signals (e.g., simple bubble grades or more sophisticated...
“time-intensity” approaches) (Eftedal et al. 2007). However, the absence of VGE is strongly associated with the absence of DCS.

The positive and negative predictive values of VGE have been explored in both divers and aviators (Nishi 1993, Kumar et al. 1992a, Kumar & Waligora 1995, Conkin et al. 1998). The desire to have a single global understanding of the relationship between VGE and DCS is frustrated because of differences in bubbles between divers and aviators, and even differences attributed to gender (Conkin 2010). Trials that produce Grade IV VGE in 50% of divers will never be sanctioned because this would result in an unacceptably high incidence of DCS, as well as a high incidence of serious DCS. However, Grade IV VGE-producing trials are routinely assigned in hypobaric depressurizations, even after conservative PBs (Webb et al. 2002). DCS incidence on the order of 20% is common, with only approximately 1% of all exposures resulting in serious DCS in NASA testing and a higher percentage in tests of protocols for the USAF (Balldin et al. 2004). Divers returning to 1 ATA from a provocative SCUBA dive may produce many small bubbles, predominately composed of N2. In contrast, aviators may produce fewer large bubbles composed of as much as 70% metabolic gases (Van Liew & Burkard 1994, 1995, Van Liew et al. 1993). Because the gas composition of VGE in divers and aviators is different, it is reasonable to expect that the association between VGE and DCS reflects this difference. In summary, a global understanding about the relationship between VGE and DCS is not yet available. The absence of this understanding results in contradictions when the experiences of divers and aviators are compared.

It is more than coincidental that VGEs are often detected in high intensity coming from a region of the body where a sign or symptom may appear. Table 7 shows that the positive predictive value for DCS of any VGE grade or of Grade III and IV is only 32 or 39% (Conkin et al. 1996a). Someone with prior knowledge of even Grade IV VGE from a particular limb in an aviator is less than 40% confident that a DCS symptom will follow. The absence of VGE has a negative predictive value of 98% based on these data, with a much lower value based on other hypobaric data (Olson et al. 1988, Balldin et al. 2002). Thus, it is more informative to know that an aviator or astronaut has no VGE in the pulmonary artery if the goal is to predict a subsequent DCS outcome (Kumar et al. 1997).

Table 7. Measures of association between VGE and DCS

<table>
<thead>
<tr>
<th>measure</th>
<th>Grades 0 – IV (n = 1,322)</th>
<th>Grades 0, III, IV (n = 1,210)</th>
</tr>
</thead>
<tbody>
<tr>
<td>sensitivity</td>
<td>0.922</td>
<td>0.917</td>
</tr>
<tr>
<td>specificity</td>
<td>0.718</td>
<td>0.787</td>
</tr>
<tr>
<td>+ predictive value</td>
<td>0.323</td>
<td>0.391</td>
</tr>
<tr>
<td>- predictive value</td>
<td>0.980</td>
<td>0.980</td>
</tr>
</tbody>
</table>

Even though a one-to-one cause-and-effect relationship between VGE and DCS does not exist, there is a consistent temporal association between VGE and DCS. Figure 8 shows this temporal pattern. Not everyone who has VGE has subsequent DCS, and a few people who do not have VGE do have DCS. The caveat here is that a similar VGE onset and recovery pattern is present in those who do and those who do not develop DCS. Any association between VGE detected in the pulmonary artery and pain-only DCS in a distant limb is subtle.
Risk of Decompression Sickness (DCS)

Figure 8. Time of VGE and DCS onset in 78 exposures in which both VGE and DCS were present (solid curve) and in 150 exposures in which only VGE was present (dashed curve). The curves, all of which are skewed to the right, are the best-imposed normal distributions on histograms.

The NASA Hypobaric Decompression Sickness Database contains data on 78 subjects with DCS onset times associated with 78 VGE onset times, with a mean TR of 1.67 ± 0.15. The mean DCS onset time was 120 ± 71 min, and the mean VGE onset time was 72 ± 55 min. In 150 other exposures, VGEs were not associated with a report of DCS. The 150 exposures associated with VGE but not DCS had a mean VGE onset time of 90 ± 65 min and a mean TR of 1.65 ± 0.19. The mean VGE onset time for all 228 exposures associated with VGEs was 84 ± 62 min. Only 4 subjects had DCS without VGE being detected. The majority of exposure individuals, a total of 317 of 549 (57.7%), had no DCS or VGE, as the goal was to validate only safe PB protocols. The same pattern held for exercise during PB, but the incidence of DCS given that VGEs were present decreased slightly from 14% to 11%. It was likely, but not certain, that an individual would report a DCS symptom after VGEs were detected if they were detected early in the altitude exposure, if the intensity or grade of VGE from a limb region increased rapidly, and if the intensity or grade of VGE remained high (Conkin et al. 1996a, 1998).

It is appropriate here to speculate on why VGEs detected in the pulmonary artery seem disconnected from the DCS outcome even when the VGEs seem to originate from a limb region. VGEs moving in the venous blood and detected at a common location throughout the cardiac cycle are far removed from the site of bubble formation, so there is no guarantee that other tissues, such as fat and skin, do not contribute VGEs to the venous return. There is no a priori reason why VGE cannot be produced in a limb region even if the critical volume of evolved gas needed to evoke a symptom has not been reached. Excess dissolved N₂ in muscles, tendons, ligaments, joints, cartilage, and other tissues can form bubbles in these tissues and can also diffuse into the low-pressure venous return where bubbles grow from micronuclei clinging to the vascular endothelium. They accumulate, grow, and then pinch off and coalesce, to be carried
with the venous return as muscle contractions “milk” the blood and bubbles into the venous return. Thus, it is understandable that VGEs detected in the pulmonary artery are only indirectly linked to DCS symptoms. However, even a weak association is helpful for visualizing the primary cause of a symptom at a distant location and the transport of excess N₂ as bubbles. Advances in ultrasound technology will soon replace speculation, with clear visual evidence of stationary bubbles growing within tissues and on the vascular endothelium.

It is preferable from a DCS standpoint to not have circulating VGEs, with or without a PFO. Blood is a complex fluid, and the blood-endothelial interface forms a complex homeostatic surface; thus, the presence of bubbles in blood and at the blood-endothelial interface could be problematic. Aviators and astronauts share one feature with divers, namely healthy lungs that provide an efficient filter for VGEs (Diesel et al. 2002). However, aviators and astronauts are not immune to the consequences of embolic overload, even if they have healthy lungs. Many factors in the aerospace environment compromise healthy lung function. These factors combined with too many bubbles entering the pulmonary circulation can put this group at high risk (Balldin et al. 2002).

In-suit Doppler Effort:

Monitoring for VGE in the pulmonary artery as the entire right-heart cardiac output enters the pulmonary circulation is the simplest approach for obtaining an unbiased assessment of the effective decompression dose, even if VGE are not directly linked to subsequent DCS. Noninvasive Doppler ultrasound bubble detection technology quickly advanced in the mid-1970s to the point where small, battery-operated devices were safe to use in operational settings. Investigators at Brooks AFB in the early 1980s proposed that a 5-mHz continuous-wave bubble detector with simple analog recording be interfaced with the U-2 aircraft pressure garment. However, scientific rationale and engineering capability were not enough to implement this system, even as a research tool. The idea was valid and the rewards were great, so efforts persist at JSC to provide an automated venous blood bubble monitor for use in the EMU. Several prototypes were developed and tested at JSC. A parallel effort was also initiated by the Russians, who eventually monitored subjects in the Orlan suit during altitude chamber flights.

The ability to acquire a stable, quality blood flow signal was verified during brief periods of μG during parabolic flight. The viscera within the chest stabilized in μG, which allowed for good signal quality even under modest body motion (Hadley et al. 1984). Technical advances continued, especially in the design of the probe. The final configuration was a triangular flat probe head with 1 transmitting and 3 receiving sensors spaced so that a rib was always spanned regardless of the probe orientation on the chest over the pulmonary artery. The sensor had to perform in a "hands off" operation once the EMU was donned. Various taping and strapping options were evaluated to maintain orientation of the probe. Techniques to maintain the ultrasound coupling between the sensor and skin were needed because one hour of use in a hypobaric environment would evaporate the ultrasound gel. Issues of suit fit with the Doppler device inside the EMU were evaluated during normal training activities at the NBL. A final design emerged where the battery module, 2.4-mHz continuous-wave ultrasound electronic module, and digital recorder module were separate on a belt worn around the waist. The system was flown on STS-87 and worn by Winston Scott while in the Shuttle, not in the EMU. The system was evaluated at 6.5 psia in 4 subjects in an altitude chamber (Test 11b) and recorded
VGE in 1 subject. Finally, the system was used in the underwater habitat *Aquarius* where astronauts on the NEEMO 5 mission wore the unit for several hours after returning from dives deeper than the 56 FSW saturation depth of the habitat. A significant finding was the recording of false-positive VGE signals. Gas entrained by swallowing liquids was detected due to the proximity of the sensor to the esophagus (Acock *et al.* 2004, Gernhardt *et al.* 2005). This was significant because astronauts are encouraged to drink water from a 32-ounce drink bag within the EMU during long EVAs. The Doppler device, training, and use of the device under real-world conditions were successful.

Despite a successful research and development program for an automated in-suit bubble detector, a final operational system did not materialize. Safety concerns about the battery-operated device within the 100% O₂ EMU environment halted the effort and also prevented exposure of an astronaut to 4.3 psia while shirtsleeve in the Shuttle or ISS airlock as a means to evaluate the device. There was also an understandable resistance to implement this system due to concerns that the results could impact future EVA assignments.
V. DCS Treatment Experience

The many signs and symptoms as a consequence of evolved gas and a review of treatment options for those afflicted are briefly described using data from NASA. The reader is also referred to Norfleet (2008), Stepanek & Webb (2008a), Balldin et al. (2004), Ryles & Pilmanis (1996), Krause & Pilmanis (2000), Muehlberger et al. (2004), Conkin et al. (2003), and Jersey et al. (2010) for descriptions of what aviators and astronauts need to avoid to stay healthy and productive, as well as treatment options if evolved gas is not prevented.

A PB protocol selected for EVAs in future Exploration-class missions will be conservative. However, even conservative PB protocols come with some risk. What should mission managers expect as far as the prevalence and characteristics of symptoms? How effective is a return to habitat pressure after the EVA to resolve symptoms? What percentage of symptoms that resolve before a return to site pressure reoccur and require initiation of a hyperbaric O\textsubscript{2} (HBO) treatment? These and other questions are addressed by discussing the 220 symptoms associated with the 119 cases of DCS that have accrued during hypobaric chamber studies conducted by NASA. Conkin et al. (2003) discussed 103 of these cases in detail from 1982-1999. These and more recent DCS cases are being analyzed with the intent to develop a DCS treatment model (Conkin et al. 2013). Additionally, the effectiveness of treating symptoms at the conclusion of an EVA is described using a bubble model.

Figure 9 shows the number of Type I symptoms associated with an approximate anatomical location. The knees and ankles contribute 139 occurrences (68%) out of 203 Type I symptom occurrences. These data reflect results where subjects were ambulatory before and during the altitude exposure, but even subjects that were not ambulatory (adynamic) before and during the exposure had pain-only symptoms predominantly in the lower body. Clearly, the lower body (feet, ankles, knees) is a primary location for DCS symptoms and is not expected to change in astronauts who ambulate on the surface of Mars or the moon.

Figure 10 shows the number of Type I symptom attributes. Pain as a symptom attribute that was constant in nature dominates how Type I symptoms were described by subjects.
Figure 9. Number of Type I symptom occurrences in 119 cases of DCS. Symptoms in toes or fingers were included in the "feet" or "hands" categories. One subject had skin symptoms (tingling) located in 7 body locations.

Figure 10. Number of Type I symptom attributes in 119 cases of DCS. Seven of the 9 cases of "tingling" symptoms came from 1 subject. The two symptoms of numbness were attributed to impaired circulation and were not neurological in origin.
Figure 11 shows the number of Type II symptom attributes from 7 cases classified as Type II DCS. The low number of Type II symptoms limit any meaningful conclusions.

![Type II symptom attributes](image)

**Figure 11.** One of 3 headaches in this figure was classified as Type I DCS. Headache and a sensation of being hot during an otherwise unremarkable 4-hr test caused the symptom of “headache” to be classified as Type I DCS in a female. However, the subject later reported having Type I symptoms and underwent HBO treatment. Chest mottling (cutis marmorata) was initially classified as Type II DCS at JSC but now exists as its own category of DCS – not Type I or Type II. It is shown on this graph in its historical context.

Once a symptom appears during a validation test, it must be completely resolved before the subject is released by the Medical Officer. Figure 12 shows the cumulative percentage of symptoms that resolved at the given pressure difference. Thirty-seven symptoms (19%) resolved at the test altitude, before repressurization; 122 symptoms (63%) resolved during repressurization; 14 symptoms (7.2%) resolved at site pressure (14.5 to 14.7 psia); and 21 symptoms (10.8%) were persistent at site pressure and resolved during HBO treatment (USN Treatment Table V or VI). Not represented in the figure are 11 symptoms that initially resolved prior to the subject being released from the test but reoccurred later and required initiation of HBO treatment. Given the lengthy denitrogenation provided to NASA subjects, 89% of 194 symptoms resolved over a pressure difference of 10.4 psia with 50% resolution over a pressure difference of just 3 psia.
Figure 12. The cumulative percentage of 194 symptoms that resolved at the given pressure difference defined as the pressure associated with symptom resolution minus the altitude test pressure, in units of psia.

Figure 13 shows NASA data on the cumulative percentage of 194 symptoms that resolved at a given pressure difference up to total recompression. A comparison of this NASA data to a much larger dataset of 1,699 resolved DCS symptoms from Muehlberger et al. (2004) reveals similarities despite the presence of approximately nine times more data from Brooks AFB. For example, 19.0% of symptoms resolved at the test altitude based on the NASA data compared with 4.4% based on the USAF data, and 81.9% of all symptoms based on the NASA data resolved before reaching site pressure compared with 88.2% based on the USAF data. Fifty percent of symptoms resolved based on the NASA data after the application of 160 mmHg of pressure compared with 138 mmHg for the USAF data. Seventy-five percent of symptoms resolved based on the NASA data after applying 340 mmHg of pressure, compared with 250 mmHg for the USAF data.
**Figure 13.** The majority of data is the same as presented in Figure 12 with an expanded x-axis and pressure difference converted to mmHg.

Figure 14 shows 3 examples to demonstrate the resolution of a Bubble Growth Index (BGI) of 14 units given a Boyle’s Law decrease in bubble volume with applied treatment pressure and the bubble-to-tissue N₂ gradient as computed with the BGI model (Gernhardt 1991). The BGI is the ratio of the final bubble radius to an initial bubble radius of 3 microns.

The first curve from the left is derived from data obtained after a 60-min PB in an astronaut exposed to 4.3 psia with return to 14.7 psia, the second curve presents data from a saturation diver with return to 41.1 psia after exposure to 14.7 psia, and the third curve is derived from data obtained after a 300-min PB in an astronaut exposed to 4.3 psia with return to 14.7 psia (5 min for all pressure transitions). The elapsed time from the start of decreased pressure (time 0) to bubble resolution is shorter in the astronaut cases, dependent on the PB time, compared with the saturation diver. The difference is due to a slight Boyle’s Law advantage during the return to site pressure (14.7 psia for the astronauts and 41.1 psia for the saturation diver) combined with a greater bubble-to-tissue N₂ gradient for the astronaut with the longer PB compared with the saturation diver.

A tentative conclusion based on only 3 examples and multiple assumptions in the BGI model is that the time is shorter to resolve a theoretical bubble for an astronaut treated with 100% O₂ at 1 ATA compared with a saturation diver treated with 100% O₂ at 2.8 ATA (his saturation pressure and the treatment pressure for the USN TT V). One other complication for the diver is the high pO₂ during treatment, a level that must be reduced during “air breaks” to prevent CNS or pulmonary O₂ toxicity. This complexity was not included in the simulation and is not a complexity that the astronaut must face because 100% O₂ at 1 ATA is well-tolerated for several hours.
Risk of Decompression Sickness (DCS)

**Figure 14.** The resolution of a 14-unit BGI given a Boyle’s Law decrease in bubble volume with applied treatment pressure and the bubble-to-tissue N\textsubscript{2} gradient. The first curve from the left is derived from data obtained after a 60-min PB in an astronaut exposed to 4.3 psia with return to 14.7 psia; the second curve represents data from a saturation diver with return to 41.1 psia after exposure to 14.7 psia; and the third curve is derived from data obtained after a 300-min PB in an astronaut exposed to 4.3 psia with return to 14.7 psia (5 min for all pressure transitions).

DCS treatment on ISS follows a flow diagram designed to treat symptoms and evolved gas by keeping the astronaut in the suit breathing 100% O\textsubscript{2} at 4.3 psid (19.0 psia) for prescribed intervals of time. A limited neurological examination is available that assesses the suited astronaut during the course of treatment. The return from 4.3 psia to even 14.7 psia on ISS causes a 71% Boyle’s Law decrease in a unit volume of gas, compared with a 64% decrease in a unit volume of gas in a diver that is treated at 2.8 ATA (41.1 psia). Remaining in the suit and pressurized to 19.0 psia causes a 77% decrease in a unit volume of gas. In the event symptoms do not resolve at 19.0 psia, the Bends Treatment Adapter (BTA) is installed without depressurizing the suit. The suit is further pressurized to 8.0 psid (22.7 psia), resulting in an 81% decrease in a unit volume of gas, significantly better than the case in a diver seeking treatment on a USN TT V. Although an effective treatment option, the use of the BTA results in an EMU that is no longer certified for EVA. A return to site pressure (see Fig. 11) is expected to resolve most symptoms, and the option to treat a persistent, recurrent, or Type II symptom at 22.7 psia with 100% O\textsubscript{2} using the BTA is expected to be effective. The option to return an astronaut to Earth for additional treatment was possible with the shuttle from the ISS but is not an option with the Russian Soyuz and will not be an option for missions to the moon, Mars, or deep space.

Providing DCS treatment options and any adjunctive therapy for Exploration-class missions should follow an evidence-based approach. The approach needs to ultimately match the most effective treatment for the anticipated risks, as providing proper medical treatment at remote
Risk of Decompression Sickness (DCS)


VI. Risk in Context of Exploration Mission Operational Scenarios
As of August 2013, there have been no reported cases of DCS during Shuttle and ISS missions due to adherence to rigorously developed PB protocols that were specifically validated for Shuttle and ISS operational environments and EVA scenarios. Although DCS risk has been greatly reduced through these PB protocols, it is at the expense of significant crew time and consumable usage. This need for significant crew time and consumables will not meet the needs of the Exploration program.

The architectures being developed by NASA for future exploration beyond low-Earth orbit differ from previous vehicles and EVA systems in terms of vehicle saturation pressures, breathing mixtures, EVA frequency, EVA durations, and pressure profiles, and they will almost certainly differ in terms of the definition of acceptable DCS risk and in-situ DCS treatment capabilities. The use of suit ports, variable-pressure EVA suits, intermittent recompressions, and possibly abbreviated purges with PB gas mixtures of less than 100% oxygen represents a paradigm shift in the approach to EVA, with the potential of reducing EVA crew overhead and consumable usage by two orders of magnitude (Abercromby et al. 2013). However, the role and impact of these variables on the overall probability of DCS is theoretical, with no empirical data available to support the theory. In addition, the acceptable level of DCS risk is dependent on treatment capability.

A. PB Protocols Meet Acceptable DCS Risk Level, but with Poor WEI and High Consumable Use

WEI is defined as EVA time divided by the amount of time spent preparing for the EVA, regardless of whether it is spent in a PB protocol or on tasks related to an EVA suit preparation. NASA’s historical µG EVA experience leads to an expectation of the threat of serious DCS being extremely small, primarily due to rigorous adherence to validated PB protocols. Outside of the shuttle staged protocol, a unifying principle of all of these PB protocols is that there is a significant use of crewmember time and consumables before they exit the airlock. Current ISS WEI is less than 0.4. This WEI accounts for PB, suit donning/doffing, and processing of the EVA suit and associated tools. While this is tolerable for ISS EVAs, primarily due to their low frequency and the pre-existing EVA timelines, it will not be acceptable for future manned exploration missions, which will rely on a robust, efficient EVA program that assumes high-frequency flexible exploration objectives of the destination target(s). Architectural assumptions for future surface exploration missions include up to multiple EVAs per person per day, which is unachievable given current spacecraft atmospheres and PB protocols.

B. Exploration Missions Need to Define WEI and EVA Goals

There are several potential DRM destinations that lie ahead in NASA’s manned exploration pathway. Each DRM has its own unique combination of DCS risk factors, and the manner in which NASA plans to address those problems must be considered in advance of final design
plans for manned mission elements. Prescribing an expected WEI target for any given DRM would drive overall design and engineering toward the most efficient use of crewmember time.

An efficient exploration program needs an efficient EVA component. Infrequent, highly specific EVAs, such as those performed for ISS assembly, were effectively managed using existing PB protocols. Exploration missions will not have these same highly specified EVA timelines, but they will rely on more real-time science objectives and prioritization to determine EVA needs. While there are different ways to manage exploration EVA, the most flexible approach is to determine a minimal denitrification strategy that allows for on-demand EVA capabilities. This will most likely be met with some type of staged denitrification protocol. Currently, a long PB time is needed before EVA from the ISS. The denitrification may be effective in reducing the P(DCS), but even effective existing PB protocols are associated with a high incidence of VGE. Significant VGE insult of the lungs at 4.3 psia increases the probability of transporting VGE through the pulmonary vasculature or through a PFO (Foster et al. 2003, Moon 2000, Pilmanis et al. 1996).

A future habitat atmosphere should have a low pN\textsubscript{2} to shorten or eliminate the PB time. One practical approach to reducing the pN\textsubscript{2} is to increase the pO\textsubscript{2} while also reducing the ambient pressure (Allen et al. 1969, Cooke & Robertson 1974, Horrigan & Waligora 1980). A balance is achieved between the increased risk of fire at high O\textsubscript{2} concentration and the decreased risk of DCS as pN\textsubscript{2} is reduced in the habitat. The concentration of O\textsubscript{2} and, therefore, the risk of fire for a given ambient pressure can be reduced further if P\textsubscript{O2} is less than 150 mmHg, but not so low as to cause significant hypoxia (Conkin & Wessel 2008). Not considered here are many other factors involved in living in a low-pressure habitat with an exotic breathing mixture, including a significant increase in electrical power for ventilation fans, increased insensible water loss (dehydration), valid issues about food preparation and steam sterilization (Brown et al. 1991, Campbell 2006), problems with voice communication (Roth 1967), and reduced response time in the event of a cabin atmosphere leak.

C. Mitigating DCS through an Exploration Atmosphere may Introduce New Concerns

The Engineering Directorate, Space and Life Sciences Directorate, Extravehicular Activity Office, and Astronaut Office all approved the proposed Exploration Atmosphere (8.0 psia / 32% O\textsubscript{2}), which was a result of the 2006 Exploration Atmospheres Working Group (EAWG). This sought-after compromise provided a balance between mild hypoxia (P\textsubscript{O2} = 117 mmHg), flammability concerns in the pressurized living space, and the availability of quick, low-overhead EVA capability with the trade of very little DCS risk (Campbell, 2006). In 2012, the results of the EAWG were re-evaluated by the Exploration Atmosphere Action Team. The Human Health and Performance subteam had the specific focus of evaluating the hypoxic symptoms potentially associated with the 8/32 atmosphere. This effort resulted in a recommendation to raise the pressure to 8.2 psia and O\textsubscript{2} to 34%, resulting in a P\textsubscript{O2} = 128 mmHg and no net change to the pN\textsubscript{2} (Norcross et al. 2013). When coupling the 8.2/34 Exploration Atmosphere with a variable-pressure EVA suit and a highly efficient suit donning/doffing technology such as the Multi Mission Space Exploration Vehicle (MMSEV) suitports, crew time and consumable use is efficiently maximized (Abercromby et al. 2013). However, there are undesired outcomes as well. In order to meet the demands of decreased pressure and acceptable flammability risk, crewmembers will live in mild hypoxia. This may
result in unrealized (or perhaps poorly understood) health consequences, or crewmembers may acclimate quickly with no hypoxic symptoms. Astronauts experienced a very similar hypoxic stress during the shuttle staged protocol at 10.2 psia / 26.5% O\textsubscript{2} environment (P\textsubscript{O}2 = 127 mmHg). This level of hypoxia was not originally considered severe enough to warrant any specific research efforts. However, data mining efforts through the Lifetime Surveillance of Astronaut Health (LSAH) and Life Science Data Archive (LSDA) repositories are currently underway to determine any evidence of hypoxia-related symptom occurrence during these flights.

D. No Exploration Atmosphere Means Longer Denitrogenation Protocols

Current and future spacesuit functionality requires decompression prior to EVA. Without the use of a staged denitrogenation protocol, such as proposed with the 8.2/34 Exploration Atmosphere, or a zero-PB EVA suit operating at higher pressures, denitrogenation protocols will remain lengthy. Much research could be performed to reduce the length of existing ISS PB protocols. Understanding how a break in PB affects P(DCS) would be a critical step. Additionally, understanding the differences in VGE, N\textsubscript{2} washout, and micronuclei generation in the space flight environment would be of great benefit. In the end, an operational mitigation strategy that relies on long O\textsubscript{2} PB as the primary strategy will result in longer more complicated EVA preparation timelines and higher consumable use and will reduce the flexibility and capabilities of exploration EVA.

An example of the consumables savings available through use of the 8.2/34 Exploration Atmosphere is the reduction in the suit purge time by 6 min per EVA, achieving 80% O\textsubscript{2} in the spacesuit rather than 95%. This modestly increases the P(DCS) risk, but the calculated savings of 0.48 lb of gas and 6 minutes per person per EVA corresponds to more than 31 hours of crew time and 1800 lb of gas and tankage under the Constellation lunar architecture (Abercromby et al. 2013).

Of the available strategies to significantly reduce denitrogenation time while maintaining acceptable DCS risk, the Exploration Atmosphere strategy is more promising than either a high-pressure EVA suit or an enhanced version of current ISS PB protocols.

E. DCS Treatment is Undefined

NASA operates under the maxim that prevention of DCS is better than treatment of DCS. Nowhere is that statement truer than when astronauts are far beyond low-Earth orbit, and effectively outside the reach of real-time medical guidance. NASA should make every attempt to first use engineering controls and then operational procedures to mitigate DCS to acceptable risk levels and then properly prepare to treat a symptomatic crewmember. There may be no hyperbaric chamber capability available during future exploration missions, but if properly designed, a variable-pressure suit port-compatible EVA suit could provide almost instantaneous repressurization to the intermediate habitat pressure (likely 8.2 psia) and, if detached from the suit port and brought inside the cabin, could provide at least an additional 8.2 psia above the ambient cabin pressure. This simple application of Boyle’s Law goes a considerable distance in resolving most Type-I DCS pain (see Section 5 DCS Treatment Experience).
VII. Gaps

We have described much of the evidence related to spaceflight DCS, and there still remain gaps in knowledge. The gaps are described in the following sub-sections and form the focus of the future NASA DCS research efforts.

A. DCS1 – We have not defined the acceptable DCS risk with respect to the work efficiency index (WEI) for exploration scenarios

Acceptable DCS risk for ISS assembly was defined as part of the PB reduction program. By validating operational PB protocols against this acceptable risk level, NASA has successfully prevented both serious Type II DCS and Type I pain-only DCS. This acceptable risk level is currently under review by the NASA Headquarters Chief Health and Medical Office to be included as a new human spaceflight standard in the EVA section of NASA-STD-3001 Volume 1. This standard will dictate the minimum standard for which all future PB protocols will need to be tested against. The focus of this standard was to protect against long- and short-term human health consequences, but it does not define any guidelines for WEI, crew time, or consumables.

The target for gap closure is the complete approval of the NASA-STD-3001 Volume 1 update for EVA purposes and then a later update to NASA-STD-3001 for a DCS risk standard related to vehicle decompressions to the Exploration Atmosphere, which exposes the entire crew to a DCS risk.

B. DCS2 – We do not know the contribution of specific DCS risk factors to the development of DCS in the Space Flight Exploration Environment

As previously discussed, it is well accepted that gas bubbles through some mechanism are the initial cause of the symptoms of DCS. This gas bubble formation and growth can potentially occur during decompressions from higher to lower ambient pressure, but the mechanisms that cause bubble formation, growth, and elimination are not well understood. It is known that physiological and environmental factors contribute to DCS, but there is a lack of information on their importance or interrelationships in the space flight environment.

The target for gap closure is to obtain an effect size as a function of individual variance for each risk factor of interest. Depending on the statistical significance of a given risk factor, it may then be included in a comprehensive DCS prediction model.

C. DCS3 – We do not know the mission related factors that contribute to DCS risk

The characteristics of the ISS EVA environment are well understood, but this is not the case with new DRMs. For instance, it is known that activity level during depressurization has a significant effect on the development of DCS. At any given depressurization, an increase in activity level increases the DCS risk. In addition, certain movements tend to be more provocative than others, possibly due to the forces generated by movement in different joints. NASA is going to locations where there is either no or little human EVA experience. Many factors contribute to DCS risk, and all of these factors need to be understood in order to provide updates to models and/or to the development of EVA simulators for PB validation trials.
The target for gap closure is to develop an EVA simulator for use in PB validation trials; to provide inputs related to WEI, EVA overhead, crew time, and consumable usage in relation to achieving acceptable DCS risk (Gap 1); and to obtain an effect size as a function of individual variance for each risk factor of interest in order to consider it for inclusion in a comprehensive DCS prediction model.

D. DCS4 – We do not know to what extent physiological and environmental factors can be incorporated and validated in a model of DCS for micro and reduced gravity

Existing DCS prediction models have differing levels of credibility for μG EVA from an Earth-normal atmosphere habitat, but none of these models are validated for the Exploration environments, including planetary gravity, the 8.2/34 Exploration Atmosphere, and high-frequency EVA. Research efforts are underway to define a DCS treatment model. There is also a need for a comprehensive DCS prediction model that is both user-friendly and applicable across all DRMs. Finally, a tissue saturation model is proposed to understand tissue saturation rates with- and without exercise conditions.

The targets for gap closure are validated DCS risk and DCS treatment models for the expected exploration environments that meet NASA-STD-7009 requirements.

E. DCS5 – We do not know what validated procedures will adequately prevent DCS

Validated procedures to prevent DCS exist for the ISS but not for Exploration Mission DRMs. Current DCS prediction models do not extrapolate to the expected Exploration environment and can only be used to develop initial estimates for Exploration protocols, which must be validated through ground testing prior to operational implementation.

The targets for gap closure are PB protocols that meet the DCS1 acceptable risk standard for future exploration missions.

F. DCS6 – We do not know what new developments related to DCS will come from other investigators

Through active involvement in DCS research for the past 30 years, the current status of DCS risk factors, treatment modalities, detection methods, and prediction models is well known to NASA, but NASA is not the only institution performing DCS research. There remains a solid academic, military, and aerospace presence interested in DCS, and their developments need to be closely monitored.

The target for this gap closure is automatically met assuming the HRP EVA Discipline team regularly reviews the scientific literature and attends relevant scientific meetings. Closure is also met through regular research plan reviews by external experts as per HRP policy.

G. DCS7 – We have not validated procedures to adequately treat DCS in the spaceflight environment should it occur

DCS treatment protocols for altitude DCS often involve hyperbaric oxygen treatment. These treatment protocols are based on aviation scenarios and assume a crewmember’s return to
Risk of Decompression Sickness (DCS)

ground. In space, this may not be possible, and we need to understand the potential for treating DCS with the use of expected in-situ resources.

Additionally, we need to consider whether there are any long-term outcomes of spaceflight DCS that need to be followed over the course of a crewmember’s life.

The target for gap closure is inputs to DCS treatment procedures for each DRM and recommendations to the LSAH project for medical tests needed to evaluate long-term health consequences of spaceflight DCS.

VIII. Conclusion

DCS is an occupational health and mission hazard that requires mitigation as an astronaut moves from a higher pressure habitat into the lower pressure EVA suit. To date, DCS has been effectively mitigated through rigorous adherence to PB protocols validated specifically for the μG EVA environment. While effective, these protocols are complex and require significant pre-flight training, inflight crew time, and consumable usage. Furthermore, utilization of the Exploration Atmosphere (8.2 psi/34% O2), suit ports, and variable-pressure suits, as well as the inability to rapidly deorbit to receive medical treatment, means that existing DCS risk mitigation protocols and data sets are not applicable to future exploration missions.

The acceptable risk for DCS has been defined in the NASA Human Spaceflight Standards; therefore, the next step will be to develop and validate procedures, protocols, and countermeasures to meet this standard effectively and efficiently for the range of nominal and off-nominal atmospheres and decompression profiles that crewmembers may experience during future exploration missions.

To improve efficiency for a sea-level atmosphere, data are needed on the potential differences in bubble formation and N2 elimination while in μG. To improve safety and efficiency for any atmosphere, data are needed to describe the consequences of a break in PB. Finally, the opportunity exists to mitigate DCS primarily through engineering controls by the use of the 8.2 psia/34% O2 Exploration Atmosphere, suit ports, and variable-pressure EVA suits. While promising, these technologies are poorly understood from a physiological perspective and will demand rigorous development and testing of DCS mitigation strategies and procedures prior to operational implementation.
IX. References


Adler HF. Dysbarism. Aeromedical review 1-64. Brooks AFB, San Antonio, TX, 1964; 64-82.


Risk of Decompression Sickness (DCS)


Risk of Decompression Sickness (DCS)


Boothby WM, Luft UC, Benson OO Jr. Gaseous nitrogen elimination. Experiments when breathing oxygen at rest and at work with comments on dysbarism. Aviat Med 1952; 23:141-76.


Brubakk AO, Neuman TS, Bennett PB, Elliot DH, eds. Bennett and Elliott’s Physiology and Medicine of Diving. 5th Ed. Saunders Ltd; 2003


Risk of Decompression Sickness (DCS)


Conkin J, Gernhardt ML, Wessel JH III. Exploiting aerobic fitness to reduce the risk of hypobaric decompression sickness. [Abstract #F6]. Undersea Hyperb Med 2007; 34:82.
Risk of Decompression Sickness (DCS)


Conkin J. Decompression sickness after air break in prebreathe described with a survival model. Aviat Space Environ Med 2011; 82:589-98.


Risk of Decompression Sickness (DCS)


Risk of Decompression Sickness (DCS)


Risk of Decompression Sickness (DCS)


Risk of Decompression Sickness (DCS)


Hills BA. Compatible atmospheres for a space suit, space station, and shuttle based on physiological principles. Aviat Space Environ Med 1985; 56:1052-8.


Krutz RW Jr, Dixon GA. The effect of exercise on bubble formation and bends susceptibility at 9,100 m (30,000 ft; 4.3 psia). Aviat Space Environ Med 1987; 58(9, Suppl.):A97-9.


Kumar KV, Waligora JM, Powell MR. Epidemiology of decompression sickness under simulated space extravehicular activities. Aviat Space Environ Med 1993; 64:1032-9.


Loftin KC, Conkin J, Powell MR. Modeling the effects of exercise during 100% oxygen prebreathe on the risk of hypobaric decompression sickness. Aviat Space Environ Med 1997; 68:199-204.


Risk of Decompression Sickness (DCS)


NASA Johnson Space Center. Investigation Report of the Type I Decompression Sickness (Bends) Incidents. NASA / Johnson Space Center Internal Report, Houston, Texas, January 22, 1988


Risk of Decompression Sickness (DCS)


Risk of Decompression Sickness (DCS)


Risk of Decompression Sickness (DCS)


Vann RD, Gerth WA.  Factors affecting tissue perfusion and efficacy of astronaut denitrogenation for extravehicular activity.  F.G. Hall Hypo / Hyperbaric Center, Duke University Medical Center, Durham, NC, 1995; 11-3.

Vann RD, Gerth WA.  Is the risk of DCS in microgravity less than on Earth?  [Abstract # 45].  Aviat Space Environ Med 1997; 68:621.


Risk of Decompression Sickness (DCS)


Weathersby PK, Gerth WA, eds. Survival analysis and maximum likelihood techniques as applied to physiological modeling. 51st Undersea and Hyperbaric Medical Society Workshop. Kensington, MD: Undersea and Hyperbaric Medical Society Inc; 2002.


Webb JT, Pilmanis AA. Breathing 100% oxygen compared with 50% oxygen:50% nitrogen reduces altitude-induced venous gas emboli. Aviat Space Environ Med 1993; 64:808-12.

Risk of Decompression Sickness (DCS)

Webb JT, Pilmanis AA, Balldin UI. Altitude decompression sickness at 7620 m following prebreathe enhanced with exercise periods. Aviat Space Environ Med 2004; 75:859-64.


X. Team

Andrew F. Abercromby, Ph.D., Wyle, Houston, TX
Johnny Conkin, Ph.D., Universities Space Research Association, Houston, TX
Joseph P. Dervay, MD, NASA Johnson Space Center, Houston, TX
Daniel T. Fitzpatrick, DO., MPH, Wyle, Houston, TX
Michael L. Gernhardt, Ph.D., NASA Johnson Space Center, Houston, TX
Jill S. Klein, MS, Wyle, Houston, TX
Jason R. Norcross, MS, Wyle, Houston, TX
Jessica R. Vos, MA, NASA Johnson Space Center, Houston, TX
James H. Wessel, III, MS, Wyle, Houston, TX

Many other individuals have also contributed to the DCS Evidence Report. It is impossible to acknowledge by name all those involved in the testing, training, and operational implementation of denitrogenation protocols used over more than 40 years of spacewalks from the Gemini, Apollo, Skylab, Shuttle, Russian Mir space station, and International Space Station programs.
## XI. List of Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-G</td>
<td>Earth-normal gravity</td>
</tr>
<tr>
<td>AFB</td>
<td>Air Force Base</td>
</tr>
<tr>
<td>AGE</td>
<td>arterial gas emboli</td>
</tr>
<tr>
<td>Ar</td>
<td>argon</td>
</tr>
<tr>
<td>ATA</td>
<td>absolute atmospheric pressure</td>
</tr>
<tr>
<td>ATM</td>
<td>atmospheric pressure</td>
</tr>
<tr>
<td>BGI</td>
<td>bubble growth index</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>BTA</td>
<td>bends treatment adapter</td>
</tr>
<tr>
<td>CEVIS</td>
<td>cycle ergometer with vibration isolation and stabilization</td>
</tr>
<tr>
<td>CM</td>
<td>cutis marmorata</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CO2</td>
<td>carbon dioxide</td>
</tr>
<tr>
<td>DCS</td>
<td>decompression sickness</td>
</tr>
<tr>
<td>DCIEM</td>
<td>Defense and Civil Institute of Environmental Medicine</td>
</tr>
<tr>
<td>ΔP</td>
<td>pressure difference</td>
</tr>
<tr>
<td>DT</td>
<td>Doppler technician</td>
</tr>
<tr>
<td>EMU</td>
<td>Extravehicular Mobility Unit</td>
</tr>
<tr>
<td>ETA</td>
<td>environmental test article</td>
</tr>
<tr>
<td>EVA</td>
<td>extravehicular activity</td>
</tr>
<tr>
<td>FFW</td>
<td>feet of fresh water</td>
</tr>
<tr>
<td>FN₂</td>
<td>fraction of nitrogen in a bubble</td>
</tr>
<tr>
<td>FSW</td>
<td>feet of sea water</td>
</tr>
<tr>
<td>ft</td>
<td>foot</td>
</tr>
<tr>
<td>GLO</td>
<td>ground-level oxygen</td>
</tr>
<tr>
<td>HBO</td>
<td>hyperbaric oxygen</td>
</tr>
<tr>
<td>hr</td>
<td>hour</td>
</tr>
<tr>
<td>ID</td>
<td>identification</td>
</tr>
<tr>
<td>ISLE</td>
<td>in-suit light exercise</td>
</tr>
<tr>
<td>ISS</td>
<td>International Space Station</td>
</tr>
<tr>
<td>JSC</td>
<td>Johnson Space Center</td>
</tr>
<tr>
<td>kg</td>
<td>kilogram</td>
</tr>
<tr>
<td>k</td>
<td>number of gas species in tissue</td>
</tr>
<tr>
<td>kPa</td>
<td>kilopascal</td>
</tr>
<tr>
<td>lbf</td>
<td>pound force</td>
</tr>
<tr>
<td>µG</td>
<td>microgravity</td>
</tr>
<tr>
<td>m</td>
<td>meter</td>
</tr>
<tr>
<td>min</td>
<td>minute</td>
</tr>
<tr>
<td>ml</td>
<td>milliliter</td>
</tr>
<tr>
<td>mmHg</td>
<td>millimeters of mercury (pressure)</td>
</tr>
<tr>
<td>MO</td>
<td>Medical Officer</td>
</tr>
<tr>
<td>n</td>
<td>sample size</td>
</tr>
<tr>
<td>N</td>
<td>Newtons of force</td>
</tr>
</tbody>
</table>
Risk of Decompression Sickness (DCS)

NASA  National Aeronautics and Space Administration
NBL  Neutral Buoyancy Laboratory
NEEMO  NASA Extreme Environment Mission Operations
\( \text{N}_2 \)  nitrogen
\( \text{O}_2 \)  oxygen
P1  initial pressure
P1\( \text{N}_2 \)  computed tissue \( \text{N}_2 \) partial pressure
P2  final pressure
PB  prebreathe
\( P(\text{DCS}) \)  probability of decompression sickness
\( P(\text{Grade IV VGE}) \)  probability of Grade IV VGE
PI  Principal Investigator
\( P(\text{Serious DCS}) \)  probability of serious decompression sickness
PFO  patent foramen ovale
\( P_1\text{N}_2 \)  inspired (wet) partial pressure of nitrogen
\( P_1\text{O}_2 \)  inspired (wet) partial pressure of oxygen
\( p\text{N}_2 \)  partial pressure of nitrogen
\( p\text{O}_2 \)  partial pressure of oxygen
PRP  Prebreathe Reduction Protocol
psia  pounds per square inch absolute
PTC  Physiological Training Chamber
\( r_c \)  critical radius
R-value  ratio-value used by NASA, equivalent to \( P1\text{N}_2 \)/P2
SCUBA  self-contained underwater breathing apparatus
SD  standard deviation
STPD  standard temperature (0 Celsius), pressure (1 ATM), dry gas
STS  Space Transportation System
TR  tissue ratio
TT V  Treatment Table V
TT VI  Treatment Table VI
U.S.  United States
USAF  United States Air Force
USN TT V  United States Navy Treatment Table V
VGE  venous gas emboli
VO\( _2 \) peak  measured peak oxygen consumption as ml*kg\(^{-1}\)*min\(^{-1}\)
WW II  World War II
Appendix A: Computer-based DCS Modeling: Description of Models

Data collected from 1982 to the present are archived in the JSC Hypobaric Decompression Sickness Database. Results from specific PB protocols were used to accept or reject the protocol for specific applications. Because each protocol is unique, it is also possible to statistically describe large subsets of data to create predictive equations (models), which we call Probabilistic Modeling. We have created two classes of predictive models: statistical and biophysical. The statistical models compute the probability of DCS based on information from our best research data or best published data in cases where our research data are insufficient to address an issue. We have also extended the methodology to create a probability model for acute mountain sickness, a transient possibility on future exploration missions. The biophysical (bubble) models provide information about bubble growth in tissue, which is then linked to the probability of DCS through logistic regression, or even through a statistical survival model.

Variables that describe a test are combined to create a decompression dose. For each dose, there is a DCS and VGE response, or outcome. The statistical process optimizes the expression for dose to compute the best probability for the response. The dose includes information about the PB procedure (exercise and rest intervals), the suit pressure, the time spent at altitude, information on whether exercise is performed at altitude, information about the person in the test (VO₂ peak, gender, age) (in some cases), and information on whether the test was performed under a microgravity simulation (adynamia).

There are multiple probability models available that describe the risk of DCS, forced descent DCS, serious DCS, VGE, and Grade IV VGE. Most, but not all, of these models are documented as contractor reports or science journal publications, and most are contained in the ATOM program; however, additional BASIC programs have been written to compute 95% confidence intervals for the best estimate of risk that are not part of the ATOM program. As new data become available, statistical and biophysical predictive models are updated. The following is a summary list of statistical probability models available to evaluate new potential PB protocols before a new protocol is proposed for testing.

**Hill Equation Model for total DCS and VGE, n = 927**

**Hill Equation Model for symptoms that would stop an EVA, n = 698**

Risk of Decompression Sickness (DCS)

Survival DCS Model, n = 1075
Regression contained in the ATOM program.


Forced Descent DCS Model, n = 4766
Regression contained in the ATOM program.

Adynamia DCS and VGE Models, n = 1401
Regression contained in the ATOM program.

Serious DCS Model, n = 79,366
Regression contained in the ATOM program.


Grade IV VGE Model, n = 549 (NASA-only data)
Reference: Conkin J. unpublished regression given the age, tissue ratio, duration of the exposure, and if the subject was adynamic or not during the exposure. Regression contained in the ATOM program.

Reference: Conkin J, Powell MR, Gernhardt ML. Age affects severity of venous gas emboli on decompression from 14.7 to 4.3 psia. Aviat. Space Environ. Med. 2003;74:1142-1150. Note: the model does not include an expression for tissue ratio, so any comparison of observed Grade IV to these estimates must be from tests “like” the tests used in this model (i.e., resting and exercise prebreathes > 180 min).


Cuff 1, 2, 4 (NASA), 4(literature) DCS Models, n=194, 914, 914, 6859
Reference: Conkin J. unpublished regressions based only on the tissue ratio. Regression contained in the ATOM program.

Exercise Adynamia DCS Models (NASA, n = 154) and (Research, n = 222) from PRP Data

Exercise Adynamia DCS Models (NASA, n = 204) from PRP Data (at conclusion of V-5 test)
Reference: Conkin J. unpublished regressions based only on the exercise tissue ratio.

USAF Altitude Decompression Sickness Risk Assessment Computer (ADRAC)
Note: The computer program runs on a PC but has limited application to the NASA EVA program.

Bubble Growth Index Model - biophysical bubble model optimized to predict hypobaric DCS
Note 1: model is currently optimized for a subset of NASA DCS data, with plans to include relevant USAF data from the Air Force Research Laboratory Altitude Decompression Sickness Research Database archived at Wright-Patterson AFB. The model has the provision to account for exercise during prebreathe, but not a micronuclei size distribution.

Risk of Decompression Sickness (DCS)

Note 2: Dr. Srinivasan made significant advances in the biophysical description of bubble growth in tissue but has since retired and did not leave any useful computer code or predictive equation based on optimization of his bubble model to empirical data. For completeness, two of his published works are documented:


Probability Model to Predict Acute Mountain Sickness

Note: Living at a high altitude with an enriched O₂ atmosphere can still result in mild hypoxia if an increase in the flammability of future spacecraft atmospheres is avoided. It is unclear what the true hypoxic dose is under these NASA-unique conditions. A non-validated statistical regression model based on limited data is available to assess the probability of acute mountain sickness.


Unit Pulmonary Toxicity Dose (UPTD) Model

Note: The use of 100% O₂ in aerospace applications causes concerns about O₂ toxicity. A mathematical expression of UPTD is available to us to address concerns about limits to hyperbaric O₂ exposure.

Regression contained in the ATOM program.